CA2516320C
(en)
|
2003-02-18 |
2015-05-26 |
Kevin Slawin |
Induced activation in dendritic cells
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
US20130266551A1
(en)
*
|
2003-11-05 |
2013-10-10 |
St. Jude Children's Research Hospital, Inc. |
Chimeric receptors with 4-1bb stimulatory signaling domain
|
CA2700573C
(en)
|
2006-09-26 |
2016-11-22 |
Cedars-Sinai Medical Center |
Cancer stem cell antigen vaccines and methods
|
US8097256B2
(en)
|
2006-09-28 |
2012-01-17 |
Cedars-Sinai Medical Center |
Cancer vaccines and vaccination methods
|
JP5779090B2
(ja)
|
2008-04-09 |
2015-09-16 |
マックスサイト インコーポレーティッド |
新規に単離された細胞の治療組成物の操作および送達
|
PL2328923T3
(pl)
|
2008-09-02 |
2016-06-30 |
Cedars Sinai Medical Center |
Epitopy CD133
|
US8415150B2
(en)
*
|
2009-02-24 |
2013-04-09 |
The Trustees Of The University Of Pennsylvania |
Methods for treating progressive multifocal leukoencephalopathy (PML)
|
US10426740B1
(en)
|
2010-08-18 |
2019-10-01 |
Avm Biotechnology, Llc |
Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
|
WO2012054509A2
(en)
|
2010-10-22 |
2012-04-26 |
Dana-Farber Cancer Institute, Inc. |
Discovery of regulatory t cells programmed to suppress an immune response
|
CN107699585A
(zh)
*
|
2010-12-09 |
2018-02-16 |
宾夕法尼亚大学董事会 |
嵌合抗原受体‑修饰的t细胞治疗癌症的用途
|
CN103748236B
(zh)
|
2011-04-15 |
2018-12-25 |
约翰·霍普金斯大学 |
安全测序***
|
AU2012325915A1
(en)
|
2011-10-20 |
2014-04-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-CD22 chimeric antigen receptors
|
WO2013063419A2
(en)
*
|
2011-10-28 |
2013-05-02 |
The Trustees Of The University Of Pennsylvania |
A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
AU2013222267A1
(en)
|
2012-02-22 |
2014-07-31 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer
|
BR112014020502A2
(pt)
|
2012-02-22 |
2019-09-24 |
Univ Pennsylvania |
sequência de ácido nucleico isolada, receptor quimérico de antígeno isolado, célula, vetor, e, métodos para estimular uma resposta imune, para fornecer uma imunidade antitumoral, para tratamento de um mamífero, para gerar e para expandir uma população de células - t, e para modular a quantidade de citocina secretada por uma célula -t
|
EP2817338B1
(en)
|
2012-02-24 |
2017-07-26 |
AbbVie Stemcentrx LLC |
Dll3 modulators and methods of use
|
AU2013235726B2
(en)
*
|
2012-03-23 |
2017-04-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
KR20220029757A
(ko)
*
|
2012-04-11 |
2022-03-08 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
B-세포 성숙 항원을 표적화하는 키메라 항원 수용체
|
EA201492222A1
(ru)
|
2012-05-25 |
2015-05-29 |
Селлектис |
Способы конструирования неаллореактивной и устойчивой к иммуносупрессии т-клетки для иммунотерапии
|
EA201590207A1
(ru)
*
|
2012-07-13 |
2015-05-29 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Композиции и способы регуляции car-т-клеток
|
MX2015000433A
(es)
*
|
2012-07-13 |
2016-04-28 |
Univ Pennsylvania |
Uso de cart19 para eliminar celulas b normales para inducir tolerancia.
|
SG11201408787PA
(en)
|
2012-07-13 |
2015-01-29 |
Univ Pennsylvania |
Enhancing activity of car t cells by co-introducing a bispecific antibody
|
DK4019041T3
(da)
*
|
2012-07-13 |
2023-04-03 |
Univ Pennsylvania |
Toksicitetshåndtering for cars antitumoraktivitet
|
KR102332322B1
(ko)
*
|
2012-07-13 |
2021-12-01 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
형질도입된 t 세포의 투여 적합성을 평가하는 방법
|
US20160235787A1
(en)
*
|
2012-07-13 |
2016-08-18 |
The Trustees Of The University Of Pennsylvania |
Epitope Spreading Associated with CAR T-Cells
|
IL269270B
(en)
|
2012-08-20 |
2022-07-01 |
Hutchinson Fred Cancer Res |
Method and preparations for cellular immunotherapy
|
AU2013312838B2
(en)
*
|
2012-09-04 |
2018-11-29 |
Cellectis |
Multi-chain chimeric antigen receptor and uses thereof
|
EP2900695B1
(en)
*
|
2012-09-27 |
2018-01-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin antibodies and methods for eliciting potent antitumor activity
|
WO2014052545A2
(en)
|
2012-09-28 |
2014-04-03 |
Dana-Farber Cancer Institute, Inc. |
Targeted expansion of qa-1-peptide-specific regulatory cd8 t cells to ameliorate arthritis
|
US9365641B2
(en)
*
|
2012-10-01 |
2016-06-14 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
WO2014055771A1
(en)
*
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Human alpha-folate receptor chimeric antigen receptor
|
WO2014055657A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
CA2889055C
(en)
*
|
2012-10-24 |
2024-01-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
M971 chimeric antigen receptors
|
WO2014070462A1
(en)
|
2012-10-29 |
2014-05-08 |
The Johns Hopkins University |
Papanicolaou test for ovarian and endometrial cancers
|
AU2013204922B2
(en)
*
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
AU2015210373B2
(en)
*
|
2012-12-20 |
2017-04-06 |
Celgene Corporation |
Chimeric antigen receptors
|
KR102417657B1
(ko)
*
|
2013-02-06 |
2022-07-07 |
안트로제네시스 코포레이션 |
개선된 특이성을 갖는 변경된 t 림프구
|
US10137182B2
(en)
|
2013-02-14 |
2018-11-27 |
Immunocellular Therapeutics, Ltd. |
Cancer vaccines and vaccination methods
|
WO2014127261A1
(en)
|
2013-02-15 |
2014-08-21 |
The Regents Of The University Of California |
Chimeric antigen receptor and methods of use thereof
|
CN105358576B
(zh)
*
|
2013-02-20 |
2020-05-05 |
诺华股份有限公司 |
使用人源化抗EGFRvIII嵌合抗原受体治疗癌症
|
WO2014130635A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
|
WO2014130879A2
(en)
|
2013-02-22 |
2014-08-28 |
Stem Centrx, Inc. |
Novel antibody conjugates and uses thereof
|
LT2961831T
(lt)
|
2013-02-26 |
2020-11-10 |
Memorial Sloan Kettering Cancer Center |
Kompozicijos ir būdai, skirti imunoterapijai
|
CA2904230A1
(en)
*
|
2013-03-05 |
2014-09-12 |
Baylor College Of Medicine |
Engager cells for immunotherapy
|
EP2970985A1
(en)
|
2013-03-14 |
2016-01-20 |
Fred Hutchinson Cancer Research Center |
Compositions and methods to modify cells for therapeutic objectives
|
US9499855B2
(en)
*
|
2013-03-14 |
2016-11-22 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
KR20150131218A
(ko)
*
|
2013-03-14 |
2015-11-24 |
벨리쿰 파마슈티컬스, 인크. |
T 세포 증식의 제어 방법
|
US9587237B2
(en)
|
2013-03-14 |
2017-03-07 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
US9657105B2
(en)
*
|
2013-03-15 |
2017-05-23 |
City Of Hope |
CD123-specific chimeric antigen receptor redirected T cells and methods of their use
|
KR102466666B1
(ko)
|
2013-03-15 |
2022-11-15 |
메모리얼 슬로안 케터링 캔서 센터 |
면역치료용 조성물 및 방법
|
US10324011B2
(en)
|
2013-03-15 |
2019-06-18 |
The Trustees Of Princeton University |
Methods and devices for high throughput purification
|
US10238690B2
(en)
|
2013-03-15 |
2019-03-26 |
Celgene Corporation |
Modified T lymphocytes comprising an inducible caspase and methods of apoptosis
|
US11493428B2
(en)
|
2013-03-15 |
2022-11-08 |
Gpb Scientific, Inc. |
On-chip microfluidic processing of particles
|
US20150064153A1
(en)
|
2013-03-15 |
2015-03-05 |
The Trustees Of Princeton University |
High efficiency microfluidic purification of stem cells to improve transplants
|
WO2014145252A2
(en)
|
2013-03-15 |
2014-09-18 |
Milone Michael C |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
WO2014160627A1
(en)
|
2013-03-25 |
2014-10-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-cd276 polypeptides, proteins, and chimeric antigen receptors
|
CA2910666A1
(en)
*
|
2013-05-03 |
2014-11-06 |
Ohio State Innovation Foundation |
Cs1-specific chimeric antigen receptor engineered immune effector cells
|
JP6603209B2
(ja)
|
2013-05-10 |
2019-11-06 |
ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ |
ソルターゼ(Sortase)を用いた生存細胞のタンパク質修飾
|
US11311575B2
(en)
*
|
2013-05-13 |
2022-04-26 |
Cellectis |
Methods for engineering highly active T cell for immunotherapy
|
FI3546572T3
(fi)
*
|
2013-05-13 |
2024-05-06 |
Cellectis |
Cd19-spesifinen kimeerinen antigeenireseptori ja sen käyttötapoja
|
US11077144B2
(en)
|
2013-05-13 |
2021-08-03 |
Cellectis |
CD19 specific chimeric antigen receptor and uses thereof
|
EP3974520A1
(en)
|
2013-05-14 |
2022-03-30 |
Board of Regents, The University of Texas System |
Human application of engineered chimeric antigen receptor (car) t-cells
|
WO2014190273A1
(en)
*
|
2013-05-24 |
2014-11-27 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor-targeting monoclonal antibodies
|
WO2014201021A2
(en)
|
2013-06-10 |
2014-12-18 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for reducing immunosupression by tumor cells
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
ES2871418T3
(es)
|
2013-08-28 |
2021-10-28 |
Abbvie Stemcentrx Llc |
Composiciones y métodos de conjugación de anticuerpos específicos de sitio
|
CN113957061A
(zh)
|
2013-08-30 |
2022-01-21 |
得克萨斯大学体系董事会 |
用于肿瘤疗法的犬尿氨酸耗竭酶的施用
|
WO2015048312A1
(en)
|
2013-09-26 |
2015-04-02 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
AU2014331667B2
(en)
|
2013-10-11 |
2019-08-22 |
Biomed Valley Discoveries, Inc. |
TEM8 antibodies and their use
|
JP6637415B2
(ja)
*
|
2013-10-15 |
2020-01-29 |
ザ スクリプス リサーチ インスティテュート |
キメラ抗原受容体t細胞スイッチおよびその使用
|
ES2845924T3
(es)
|
2013-10-15 |
2021-07-28 |
Scripps Research Inst |
Interruptores de células T con receptores de antígenos quiméricos peptídicos y usos de los mismos
|
EP3057986B1
(en)
*
|
2013-10-17 |
2017-12-27 |
National University of Singapore |
Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors
|
US10144770B2
(en)
|
2013-10-17 |
2018-12-04 |
National University Of Singapore |
Chimeric receptors and uses thereof in immune therapy
|
CN104561069A
(zh)
*
|
2013-10-23 |
2015-04-29 |
深圳先进技术研究院 |
含重组嵌合抗原受体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
|
US20160280798A1
(en)
|
2013-11-06 |
2016-09-29 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Service |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
US20150140036A1
(en)
*
|
2013-11-13 |
2015-05-21 |
Novartis Institutes For Biomedical Research, Inc. |
Low, immune enhancing, dose mtor inhibitors and uses thereof
|
AU2014352638B2
(en)
|
2013-11-25 |
2018-08-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors to control HIV infection
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
US11725237B2
(en)
|
2013-12-05 |
2023-08-15 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
SG11201604565WA
(en)
|
2013-12-06 |
2016-07-28 |
Us Health |
Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
|
CN116478927A
(zh)
*
|
2013-12-19 |
2023-07-25 |
诺华股份有限公司 |
人间皮素嵌合抗原受体及其用途
|
AU2014368892B2
(en)
|
2013-12-20 |
2019-06-13 |
Fred Hutchinson Cancer Center |
Tagged chimeric effector molecules and receptors thereof
|
JP6793902B2
(ja)
|
2013-12-20 |
2020-12-02 |
ノバルティス アーゲー |
調節可能キメラ抗原受容体
|
NZ721908A
(en)
|
2013-12-20 |
2022-12-23 |
Massachusetts Gen Hospital |
Combination therapy with neoantigen vaccine
|
JP2017504601A
(ja)
*
|
2013-12-20 |
2017-02-09 |
セレクティスCellectis |
免疫療法のためにマルチインプットシグナル感受性t細胞を操作する方法
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
ES2767423T3
(es)
*
|
2014-01-13 |
2020-06-17 |
Hope City |
Receptores de antígenos quiméricos (CARS) con mutaciones en la región del espaciador Fc y métodos para su uso
|
EP3097117B1
(en)
|
2014-01-21 |
2023-10-04 |
Novartis Ag |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
US10323077B2
(en)
*
|
2014-02-10 |
2019-06-18 |
Emory University |
Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
|
TR201819571T4
(tr)
*
|
2014-02-14 |
2019-01-21 |
Cellectis |
Hem immün hücrelerde hem de patolojik hücrelerde bulunan antijenleri hedef almak amacıyla değiştirilmiş immünoterapiye yönelik hücreler.
|
SG11201606625RA
(en)
|
2014-02-14 |
2016-09-29 |
Immune Design Corp |
Immunotherapy of cancer through combination of local and systemic immune stimulation
|
EP3104866A4
(en)
*
|
2014-02-14 |
2017-08-02 |
Bellicum Pharmaceuticals, Inc. |
Methods for activating t cells using an inducible chimeric polypeptide
|
CA3190002A1
(en)
*
|
2014-02-14 |
2015-08-20 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors and methods of making
|
US10308721B2
(en)
|
2014-02-21 |
2019-06-04 |
Abbvie Stemcentrx Llc |
Anti-DLL3 antibodies and drug conjugates for use in melanoma
|
US10196608B2
(en)
|
2014-02-21 |
2019-02-05 |
Cellectis |
Method for in situ inhibition of regulatory T cells
|
CN106279434B
(zh)
*
|
2014-02-24 |
2020-07-03 |
西比曼生物科技(上海)有限公司 |
工程化cd20靶向性的nkt细胞及其制备方法和应用
|
AU2015222917A1
(en)
|
2014-02-27 |
2016-09-15 |
Lycera Corporation |
Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
|
CN104877028A
(zh)
*
|
2014-02-28 |
2015-09-02 |
百奥迈科生物技术有限公司 |
抗dota嵌合抗原受体修饰的t细胞及其抗肿瘤的应用
|
US11385233B2
(en)
|
2015-03-05 |
2022-07-12 |
Autolus Limited |
Methods of depleting malignant T-cells
|
US11982672B2
(en)
|
2014-03-05 |
2024-05-14 |
Autolus Limited |
Methods
|
US20170066827A1
(en)
*
|
2014-03-05 |
2017-03-09 |
Ucl Business Plc |
Chimeric antigen receptor
|
GB201403972D0
(en)
|
2014-03-06 |
2014-04-23 |
Ucl Business Plc |
Chimeric antigen receptor
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
WO2015140268A1
(en)
*
|
2014-03-19 |
2015-09-24 |
Cellectis |
Cd123 specific chimeric antigen receptors for cancer immunotherapy
|
WO2015143224A1
(en)
*
|
2014-03-19 |
2015-09-24 |
Ambrx, Inc. |
Chimeric antigen receptor-modified t-cells
|
IL295906A
(en)
|
2014-03-21 |
2022-10-01 |
Abbvie Inc |
Antibodies against egfr and drug antibody conjugates
|
JP6673848B2
(ja)
*
|
2014-04-03 |
2020-03-25 |
セレクティスCellectis |
癌免疫療法のためのcd33特異的キメラ抗原受容体
|
EP3129470B1
(en)
*
|
2014-04-07 |
2021-04-07 |
Novartis Ag |
Treatment of cancer using anti-cd19 chimeric antigen receptor
|
CA2945162A1
(en)
|
2014-04-07 |
2015-10-15 |
Minerva Biotechnologies Corporation |
Use of an anti-nme antibody for treatment or prevention of cancer
|
JP6765968B2
(ja)
*
|
2014-04-10 |
2020-10-07 |
シアトル チルドレンズ ホスピタル, ディービーエー シアトル チルドレンズ リサーチ インスティテュート |
薬物制御による導入遺伝子の発現
|
EP3131927B8
(en)
*
|
2014-04-14 |
2020-12-23 |
Cellectis |
Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
|
RU2763795C2
(ru)
|
2014-04-23 |
2022-01-11 |
Джуно Терапьютикс, Инк. |
Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии
|
WO2015164739A1
(en)
*
|
2014-04-25 |
2015-10-29 |
Bluebird Bio, Inc. |
Kappa/lambda chimeric antigen receptors
|
US10774343B2
(en)
|
2014-04-25 |
2020-09-15 |
Bluebird Bio, Inc. |
MND promoter chimeric antigen receptors
|
PT3134095T
(pt)
|
2014-04-25 |
2020-07-02 |
Bluebird Bio Inc |
Métodos melhorados para a produção de terapias com células adotivas
|
GB2540694A
(en)
*
|
2014-04-29 |
2017-01-25 |
Seattle Children's Hospital (Dba Seattle Children's Res Institute) |
CCR5 disruption of cells expressing anti-hiv chimeric antigen receptor (CAR) derived from broadly neutralizing antibodies
|
WO2015168469A1
(en)
|
2014-05-02 |
2015-11-05 |
Emory University |
Humanized variable lymphocyte receptors (vlr) and compositions and uses related thereto
|
GB201407852D0
(en)
|
2014-05-02 |
2014-06-18 |
Iontas Ltd |
Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
|
CN107074929B
(zh)
*
|
2014-05-02 |
2021-09-03 |
宾夕法尼亚大学董事会 |
嵌合自身抗体受体t细胞的组合物和方法
|
JP6728061B2
(ja)
|
2014-05-05 |
2020-07-22 |
リセラ・コーポレイションLycera Corporation |
RORγアゴニストとして用いるテトラヒドロキノリンスルホンアミド及び関連化合物ならびに疾患の治療
|
EP3209641A4
(en)
|
2014-05-05 |
2018-06-06 |
Lycera Corporation |
Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease
|
KR102110187B1
(ko)
|
2014-05-14 |
2020-05-14 |
카르스젠 테라퓨틱스 리미티드 |
키메라 항원 수용체 단백질을 코딩하는 핵산 및 키메라 항원 수용체 단백질을 발현하는 t 림프구
|
JP6694875B2
(ja)
|
2014-05-15 |
2020-05-20 |
ナショナル ユニヴァーシティ オブ シンガポール |
改変ナチュラルキラー細胞及びその使用
|
AU2015270912B9
(en)
|
2014-06-02 |
2021-01-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors targeting CD-19
|
JP6663359B2
(ja)
|
2014-06-06 |
2020-03-11 |
ブルーバード バイオ, インコーポレイテッド |
改善されたt細胞組成物
|
US20180134795A1
(en)
*
|
2014-06-17 |
2018-05-17 |
Cellectis |
Cd123 specific multi-chain chimeric antigen receptor
|
GB201506423D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Tc Biopharm Ltd |
Gamma delta T cells and uses thereof
|
US10738278B2
(en)
|
2014-07-15 |
2020-08-11 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
WO2016014530A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
KR20170037625A
(ko)
*
|
2014-07-21 |
2017-04-04 |
노파르티스 아게 |
Cll-1 키메라 항원 수용체를 사용한 암의 치료
|
TWI750110B
(zh)
|
2014-07-21 |
2021-12-21 |
瑞士商諾華公司 |
使用人類化抗-bcma嵌合抗原受體治療癌症
|
AU2015292755B2
(en)
|
2014-07-21 |
2020-11-12 |
Novartis Ag |
Treatment of cancer using a CD33 chimeric antigen receptor
|
AU2015292590B2
(en)
|
2014-07-24 |
2020-01-16 |
2Seventy Bio, Inc. |
BCMA chimeric antigen receptors
|
CN107074973A
(zh)
*
|
2014-07-29 |
2017-08-18 |
辉瑞大药厂 |
用于癌症免疫疗法的EGFRvIII特异性嵌合抗原受体
|
EP3453406B1
(en)
*
|
2014-07-29 |
2021-04-14 |
Cellectis |
Ror1 (ntrkr1) specific chimeric antigen receptors for cancer immunotherapy
|
EP3194432B1
(en)
|
2014-07-31 |
2019-04-10 |
Cellectis |
Ror1 specific multi-chain chimeric antigen receptor
|
EP3174546B1
(en)
|
2014-07-31 |
2019-10-30 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing t-cells
|
CA2958200A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
|
HUE049218T2
(hu)
|
2014-08-19 |
2020-10-28 |
Novartis Ag |
Anti-CD123 kiméra antigénreceptor (CAR) rák kezelésében történõ alkalmazásra
|
EP3186274B1
(en)
|
2014-08-27 |
2021-10-06 |
Dana-Farber Cancer Institute, Inc. |
Intracellular osteopontin regulates the lineage commitment of lymphoid subsets
|
TWI751102B
(zh)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
ES2688035T3
(es)
*
|
2014-08-29 |
2018-10-30 |
Gemoab Monoclonals Gmbh |
Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
|
US9975959B2
(en)
|
2014-08-29 |
2018-05-22 |
Board Of Regents, The University Of Texas System |
Administration of kynurenine depleting enzymes for tumor therapy
|
US10888608B2
(en)
|
2014-09-02 |
2021-01-12 |
Bellicum Pharmaceuticals, Inc. |
Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides
|
EP3699188A1
(en)
*
|
2014-09-04 |
2020-08-26 |
Cellectis |
5t4 (tpbg) specific chimeric antigen receptors for cancer immunotherapy
|
CA2972714A1
(en)
|
2014-09-09 |
2016-03-17 |
Unum Therapeutics |
Chimeric receptors and uses thereof in immune therapy
|
RU2718914C2
(ru)
|
2014-09-13 |
2020-04-15 |
Новартис Аг |
Сочетанные способы лечения с использованием ингибиторов alk
|
CA2961609C
(en)
|
2014-09-17 |
2023-03-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-cd276 antibodies (b7h3)
|
CA2961636A1
(en)
|
2014-09-17 |
2016-03-24 |
Boris ENGELS |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
CA2961654A1
(en)
*
|
2014-09-19 |
2016-03-24 |
City Of Hope |
Costimulatory chimeric antigen receptor t cells targeting il13r.alpha.2
|
LT3200815T
(lt)
*
|
2014-10-02 |
2021-07-26 |
The Wistar Institute Of Anatomy And Biology |
Būdai ir kompozicijos, skirti vėžio gydymui
|
ES2774448T3
(es)
|
2014-10-03 |
2020-07-21 |
Novartis Ag |
Terapias de combinación
|
JP2017531430A
(ja)
*
|
2014-10-07 |
2017-10-26 |
セレクティスCellectis |
Carによって誘導される免疫細胞の活性を調節するための方法
|
KR20170068504A
(ko)
|
2014-10-08 |
2017-06-19 |
노파르티스 아게 |
키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
|
SG11201702391RA
(en)
*
|
2014-10-09 |
2017-04-27 |
Univ Yamaguchi |
Car expression vector and car-expressing t cells
|
PL3207130T3
(pl)
|
2014-10-14 |
2020-02-28 |
Halozyme, Inc. |
Kompozycje deaminazy adenozyny 2 (ada2), jej warianty i sposoby ich zastosowania
|
US10507219B2
(en)
|
2014-10-20 |
2019-12-17 |
Juno Therapeutics, Inc. |
Methods and compositions for dosing in adoptive cell therapy
|
ES2910227T3
(es)
*
|
2014-10-31 |
2022-05-12 |
Univ Pennsylvania |
Composición y métodos para la estimulación y expansión de células T
|
CA2964953A1
(en)
|
2014-10-31 |
2016-05-06 |
The Trustees Of The University Of Pennsylvania |
Altering gene expression in cart cells and uses thereof
|
DK3215601T3
(da)
|
2014-11-05 |
2020-06-15 |
Juno Therapeutics Inc |
Fremgangsmåder til transduktion og celleforarbejdning
|
JP2017535284A
(ja)
|
2014-11-05 |
2017-11-30 |
ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム |
免疫エフェクター細胞の拡大のための遺伝子改変免疫エフェクター細胞及び遺伝子操作細胞
|
US10570186B2
(en)
|
2014-11-05 |
2020-02-25 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (CAR) to selectively target protein complexes
|
US20170363629A1
(en)
*
|
2014-11-05 |
2017-12-21 |
Board Of Regents, The University Of Texas System |
Biomarkers and targets for cancer immunotherapy
|
FI3218005T3
(fi)
|
2014-11-12 |
2023-03-31 |
Seagen Inc |
Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
CN105601746B
(zh)
*
|
2014-11-21 |
2021-02-19 |
三生国健药业(上海)股份有限公司 |
一种嵌合Fc受体的融合蛋白及其制备方法和应用
|
MX2017007138A
(es)
*
|
2014-12-03 |
2017-08-28 |
Juno Therapeutics Inc |
Metodos y composiciones para terapia celular adoptiva.
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
KR20230159637A
(ko)
|
2014-12-05 |
2023-11-21 |
메모리얼 슬로안 케터링 캔서 센터 |
G-단백질 커플화 수용체를 표적화하는 항체 및 이의 사용 방법
|
US10821161B2
(en)
|
2014-12-05 |
2020-11-03 |
City Of Hope |
CS1 targeted chimeric antigen receptor-modified T cells
|
AU2015357533B2
(en)
|
2014-12-05 |
2021-10-07 |
Eureka Therapeutics, Inc. |
Antibodies targeting B-cell maturation antigen and methods of use
|
SG10201900931XA
(en)
*
|
2014-12-05 |
2019-02-27 |
Memorial Sloan Kettering Cancer Center |
Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
|
HUE057777T2
(hu)
|
2014-12-05 |
2022-06-28 |
Memorial Sloan Kettering Cancer Center |
Kiméra antigén receptorok, amelyek G-fehérje-kapcsolt receptort céloznak meg, és a receptorok alkalmazásai
|
US10689456B2
(en)
*
|
2014-12-08 |
2020-06-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-CD70 chimeric antigen receptors
|
EP3230441A4
(en)
|
2014-12-12 |
2018-10-03 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scaav
|
LT3230321T
(lt)
|
2014-12-12 |
2019-12-10 |
Bluebird Bio Inc |
Bcma chimeriniai antigeno receptoriai
|
CA2971186A1
(en)
|
2014-12-15 |
2016-06-23 |
The Regents Of The University Of California |
Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
|
WO2016100232A1
(en)
|
2014-12-15 |
2016-06-23 |
The Regents Of The University Of California |
Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
|
EP3757211A1
(en)
|
2014-12-19 |
2020-12-30 |
The Broad Institute, Inc. |
Methods for profiling the t-cell-receptor repertoire
|
US10975442B2
(en)
|
2014-12-19 |
2021-04-13 |
Massachusetts Institute Of Technology |
Molecular biomarkers for cancer immunotherapy
|
DK3560953T3
(da)
|
2014-12-24 |
2024-04-02 |
Autolus Ltd |
Celle
|
EP3240803B1
(en)
|
2014-12-29 |
2021-11-24 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
MA41346A
(fr)
|
2015-01-12 |
2017-11-21 |
Juno Therapeutics Inc |
Eléments régulateurs post-transcriptionnels d'hépatite modifiée
|
WO2016115482A1
(en)
|
2015-01-16 |
2016-07-21 |
Novartis Pharma Ag |
Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
|
JP6865688B2
(ja)
|
2015-01-16 |
2021-04-28 |
ジュノー セラピューティクス インコーポレイテッド |
Ror1に特異的な抗体およびキメラ抗原受容体
|
EP3250602A1
(en)
|
2015-01-26 |
2017-12-06 |
Cellectis |
T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
|
EP3250587B1
(en)
*
|
2015-01-29 |
2020-03-25 |
Regents of the University of Minnesota |
Chimeric antigen receptors, compositions, and methods
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
US10765699B2
(en)
|
2015-02-06 |
2020-09-08 |
National University Of Singapore |
Methods for enhancing efficacy of therapeutic immune cells
|
AU2016219511B2
(en)
|
2015-02-09 |
2020-11-12 |
Research Development Foundation |
Engineered immunoglobulin Fc polypeptides displaying improved complement activation
|
US20160228544A1
(en)
*
|
2015-02-11 |
2016-08-11 |
Ensysce Biosciences, Inc. |
Single Walled Carbon Nanotube Polynucleotide Complexes and Methods Related Thereto
|
CA2977350C
(en)
|
2015-02-20 |
2022-08-23 |
Ohio State Innovation Foundation |
Bivalent antibody directed against nkg2d and tumor associated antigens
|
MA41613A
(fr)
*
|
2015-02-23 |
2018-01-02 |
Abbvie Stemcentrx Llc |
Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
|
BR112017017884A2
(pt)
|
2015-02-24 |
2018-04-10 |
Univ California |
switches transcricionais desencadeados por ligação e métodos de uso dos mesmos
|
KR20170117095A
(ko)
|
2015-02-24 |
2017-10-20 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
유전적으로 변형된 t 세포 선택 방법
|
EP3261651B1
(en)
|
2015-02-27 |
2022-05-04 |
iCell Gene Therapeutics LLC |
Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
|
US10195272B2
(en)
|
2015-03-02 |
2019-02-05 |
The Nemours Foundation |
Adoptive t-cell therapy using FcεRI-based chimeric antigen receptors for treating IgE-mediated allergic diseases
|
CN108410892B
(zh)
|
2015-03-02 |
2021-05-28 |
上海斯丹赛生物技术有限公司 |
降低由pd-l1诱导的免疫耐受性
|
AU2016226022B2
(en)
|
2015-03-05 |
2020-07-09 |
Fred Hutchinson Cancer Center |
Immunomodulatory fusion proteins and uses thereof
|
CN107614062A
(zh)
|
2015-03-12 |
2018-01-19 |
加利福尼亚大学董事会 |
用RORγ抑制剂治疗癌症的方法
|
US10738116B2
(en)
|
2015-03-19 |
2020-08-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Dual specific anti-CD22-anti-CD19 chimeric antigen receptors
|
LT3271389T
(lt)
|
2015-03-20 |
2020-05-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizuojantys antikūnai prieš gp120 ir jų panaudojimas
|
US10800828B2
(en)
|
2015-03-26 |
2020-10-13 |
The Scripps Research Institute |
Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
|
CN107530427A
(zh)
*
|
2015-03-27 |
2018-01-02 |
南加利福尼亚大学 |
针对用于实体肿瘤的治疗的lhr的car t细胞疗法
|
JP6843062B2
(ja)
*
|
2015-03-27 |
2021-03-17 |
ユニバーシティ オブ サザン カリフォルニア |
Car t細胞免疫療法のための新規標的としてのhla−g
|
CA2981304C
(en)
*
|
2015-04-02 |
2024-01-02 |
Memorial Sloan Kettering Cancer Center |
Tnfrsf14/hvem proteins and methods of use thereof
|
US20180208658A1
(en)
|
2015-04-03 |
2018-07-26 |
Eureka Therapeutics, Inc. |
Constructs targeting afp peptide/mhc complexes and uses thereof
|
WO2016164308A1
(en)
|
2015-04-06 |
2016-10-13 |
Subdomain, Llc |
De novo binding domain containing polypeptides and uses thereof
|
CA2981979A1
(en)
|
2015-04-06 |
2016-10-13 |
Jianhua Yu |
Egfr-directed car therapy for glioblastoma
|
PL3280729T3
(pl)
|
2015-04-08 |
2022-08-22 |
Novartis Ag |
Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
|
WO2016168773A2
(en)
|
2015-04-15 |
2016-10-20 |
The California Institute For Biomedical Research |
Optimized pne-based chimeric receptor t cell switches and uses thereof
|
WO2016166568A1
(en)
|
2015-04-16 |
2016-10-20 |
Juno Therapeutics Gmbh |
Methods, kits and apparatus for expanding a population of cells
|
CN108473957A
(zh)
|
2015-04-17 |
2018-08-31 |
诺华股份有限公司 |
改善嵌合抗原受体表达细胞的功效和扩增的方法
|
US20180298068A1
(en)
|
2015-04-23 |
2018-10-18 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
JP2018513201A
(ja)
|
2015-04-25 |
2018-05-24 |
ザ ジェネラル ホスピタル コーポレイション |
抗fugetactic剤と抗癌剤の併用療法、および、癌の治療のための組成物
|
US20180355318A1
(en)
*
|
2015-04-29 |
2018-12-13 |
Fred Hutchinson Cancer Research Center |
Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
|
US11827904B2
(en)
|
2015-04-29 |
2023-11-28 |
Fred Hutchinson Cancer Center |
Modified stem cells and uses thereof
|
AU2016255535A1
(en)
*
|
2015-04-30 |
2017-11-16 |
University Of Southern California |
Secretory TNT CAR cell immunotherapy
|
WO2016174652A1
(en)
|
2015-04-30 |
2016-11-03 |
Technion Research & Development Foundation Limited |
Chimeric antigen receptors and methods of their use
|
US10925972B2
(en)
|
2015-05-01 |
2021-02-23 |
The Regents Of The University Of California |
Glycan-dependent immunotherapeutic molecules
|
EP3292119A4
(en)
|
2015-05-05 |
2018-10-03 |
Lycera Corporation |
DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
|
PL3291679T3
(pl)
|
2015-05-06 |
2022-04-25 |
Snipr Technologies Limited |
Zmiana populacji drobnoustrojowych i modyfikowanie mikrobioty
|
US10968426B2
(en)
|
2015-05-08 |
2021-04-06 |
President And Fellows Of Harvard College |
Universal donor stem cells and related methods
|
US11253616B2
(en)
|
2017-09-06 |
2022-02-22 |
The Trustees Of The University Of Pennsylvania |
Small molecules for dual function positron emission tomography (PET) and cell suicide switches
|
US20200316231A1
(en)
*
|
2015-05-10 |
2020-10-08 |
The Trustees Of The University Of Pennsylvania |
Compositions And Methods For Imaging Immune Cells
|
WO2016180467A1
(en)
*
|
2015-05-11 |
2016-11-17 |
Biontech Cell & Gene Therapies Gmbh |
Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
|
WO2016187068A1
(en)
|
2015-05-15 |
2016-11-24 |
The General Hospital Corporation |
Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
|
EP3298032A1
(en)
*
|
2015-05-18 |
2018-03-28 |
Bluebird Bio, Inc. |
Anti-ror1 chimeric antigen receptors
|
CA2986254A1
(en)
|
2015-05-18 |
2016-11-24 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
BR112017024732A2
(pt)
|
2015-05-20 |
2018-07-31 |
Novartis Ag |
combinação farmacêutica de everolimus com dactolisibe
|
US10434153B1
(en)
|
2015-05-20 |
2019-10-08 |
Kim Leslie O'Neill |
Use of car and bite technology coupled with an scFv from an antibody against human thymidine kinase 1 to specifically target tumors
|
EP3298046A1
(en)
|
2015-05-20 |
2018-03-28 |
Cellectis |
Anti-gd3 specific chimeric antigen receptors for cancer immunotherapy
|
US10835585B2
(en)
|
2015-05-20 |
2020-11-17 |
The Broad Institute, Inc. |
Shared neoantigens
|
AU2016268403A1
(en)
*
|
2015-05-28 |
2017-12-07 |
Armo Biosciences, Inc. |
Pegylated interleukin-10 for use in treating cancer
|
SI3302507T1
(sl)
|
2015-05-28 |
2023-10-30 |
The United States of America, as represented by The Secretary, Department of Health and Human Services, |
Diagnostični postopki za t celično terapijo
|
KR20230147769A
(ko)
*
|
2015-05-28 |
2023-10-23 |
카이트 파마 인코포레이티드 |
T 세포 요법을 위해 환자를 컨디셔닝하는 방법
|
EP3303586A1
(en)
|
2015-05-29 |
2018-04-11 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
WO2016196384A1
(en)
|
2015-05-29 |
2016-12-08 |
Fred Hutchinson Cancer Research Center |
Compositions for cellular immunotherapy
|
CN107849096B
(zh)
|
2015-05-30 |
2022-05-24 |
分子模板公司 |
去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
|
WO2016197064A1
(en)
|
2015-06-04 |
2016-12-08 |
Epstein Alan L |
Lym-1 and lym-2 targeted car cell immunotherapy
|
GB2554608B
(en)
*
|
2015-06-05 |
2022-04-06 |
Novartis Ag |
Flow-through paramagnetic particle-based cell separation and paramagnetic particle removal
|
EP3307319A4
(en)
|
2015-06-09 |
2019-05-22 |
Memorial Sloan Kettering Cancer Center |
ANTIBODIES SPECIFIC TO T-CELL RECEPTORS SPECIFIC TO EBV LATENT 2A MEMBRANE PROTEIN PRESENTED BY HUMAN HLA
|
IL309167A
(en)
|
2015-06-10 |
2024-02-01 |
Immunitybio Inc |
Modified NK-92 cells for cancer treatment
|
AU2016276947A1
(en)
|
2015-06-11 |
2017-12-14 |
Lycera Corporation |
Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
|
ES2961346T3
(es)
|
2015-06-12 |
2024-03-11 |
Lentigen Tech Inc |
Procedimiento para tratar cáncer con células T modificadas genéticamente
|
CN105177031B
(zh)
*
|
2015-06-12 |
2018-04-24 |
北京艺妙神州医疗科技有限公司 |
嵌合抗原受体修饰的t细胞及其用途
|
US20160361360A1
(en)
*
|
2015-06-12 |
2016-12-15 |
Immunomedics, Inc. |
Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
|
EP3436575A1
(en)
|
2015-06-18 |
2019-02-06 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
CN115925971A
(zh)
|
2015-06-19 |
2023-04-07 |
塞巴斯蒂安·科博尔德 |
Pd-1-cd28融合蛋白及其在医学中的用途
|
WO2017222593A1
(en)
|
2016-06-24 |
2017-12-28 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptors (cars), compositions and methods thereof
|
US11173179B2
(en)
|
2015-06-25 |
2021-11-16 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
|
AU2016283102B2
(en)
|
2015-06-25 |
2021-03-11 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptors (CARs), compositions and methods of use thereof
|
US11059880B2
(en)
|
2015-06-30 |
2021-07-13 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Redirected cells with MHC chimeric receptors and methods of use in immunotherapy
|
MA42902A
(fr)
*
|
2015-07-08 |
2018-05-16 |
Univ Johns Hopkins |
Lymphocytes infiltrant la moelle (mil) en tant que source de lymphocytes t pour une thérapie par des récepteurs chimériques d'un antigène (car)
|
WO2017011316A1
(en)
*
|
2015-07-10 |
2017-01-19 |
The Trustees Of The University Of Pennsylvania |
Treatment of a canine cd20 positive disease or condition using a canine cd20-specific chimeric antigen receptor
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
US10829735B2
(en)
|
2015-07-21 |
2020-11-10 |
The Trustees Of The University Of Pennsylvania |
Methods for improving the efficacy and expansion of immune cells
|
US10493139B2
(en)
|
2015-07-24 |
2019-12-03 |
Innovative Cellular Therapeutics CO., LTD. |
Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
|
JP7032304B2
(ja)
|
2015-07-28 |
2022-03-08 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
キメラ抗原受容体を発現する改変された単球/マクロファージおよびその使用
|
GB2595063B
(en)
|
2015-07-31 |
2022-03-09 |
Univ Minnesota |
Modified cells and methods of therapy
|
JP6751493B2
(ja)
*
|
2015-08-05 |
2020-09-09 |
セルレブメド インコーポレーテッド |
キメラ抗原受容体及びキメラ抗原受容体が発現されたt細胞
|
CA2994829A1
(en)
|
2015-08-07 |
2017-02-16 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Bispecific car t-cells for solid tumor targeting
|
US11667691B2
(en)
|
2015-08-07 |
2023-06-06 |
Novartis Ag |
Treatment of cancer using chimeric CD3 receptor proteins
|
US11286531B2
(en)
|
2015-08-11 |
2022-03-29 |
The Johns Hopkins University |
Assaying ovarian cyst fluid
|
US11352439B2
(en)
|
2015-08-13 |
2022-06-07 |
Kim Leslie O'Neill |
Macrophage CAR (MOTO-CAR) in immunotherapy
|
CN106467906B
(zh)
*
|
2015-08-20 |
2019-09-27 |
北京马力喏生物科技有限公司 |
构建体、转基因淋巴细胞及其制备方法和用途
|
US10976232B2
(en)
|
2015-08-24 |
2021-04-13 |
Gpb Scientific, Inc. |
Methods and devices for multi-step cell purification and concentration
|
CN108348551A
(zh)
*
|
2015-08-28 |
2018-07-31 |
宾夕法尼亚大学董事会 |
表达嵌合细胞内信号传导分子的细胞的方法和组合物
|
CN108135932A
(zh)
*
|
2015-08-28 |
2018-06-08 |
宾夕法尼亚大学董事会 |
表达嵌合细胞内信号传导分子的细胞的方法和组合物
|
WO2017040380A2
(en)
|
2015-08-28 |
2017-03-09 |
Research Development Foundation |
Engineered antibody fc variants
|
WO2017040529A1
(en)
*
|
2015-08-31 |
2017-03-09 |
Bluebird Bio, Inc. |
Anti-sialyl tn chimeric antigen receptors
|
US11747346B2
(en)
|
2015-09-03 |
2023-09-05 |
Novartis Ag |
Biomarkers predictive of cytokine release syndrome
|
WO2017041143A1
(en)
*
|
2015-09-11 |
2017-03-16 |
Ctm@Crc Ltd. |
Chimeric antigen receptors and uses thereof
|
MA44909A
(fr)
|
2015-09-15 |
2018-07-25 |
Acerta Pharma Bv |
Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
|
AU2016324303A1
(en)
*
|
2015-09-18 |
2018-04-26 |
The General Hospital Corporation Dba Massachusetts General Hospital |
Modified T-cells having anti-fugetactic properties and uses thereof
|
EP3349797A4
(en)
|
2015-09-18 |
2019-06-12 |
The General Hospital Corporation Dba Massachusetts General Hospital |
LOCALIZED DELIVERY OF ANTICHIMIOREPULSION AGENT FOR THE TREATMENT OF CANCER
|
EA201890782A1
(ru)
*
|
2015-09-22 |
2018-09-28 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Способ перенацеливания t-клеток для лечения инфекции hiv
|
EP3352791B1
(en)
|
2015-09-24 |
2019-10-30 |
AbVitro LLC |
Hiv antibody compositions and methods of use
|
WO2017053902A1
(en)
|
2015-09-25 |
2017-03-30 |
Abvitro Llc |
High throughput process for t cell receptor target identification of natively-paired t cell receptor sequences
|
WO2017058752A1
(en)
*
|
2015-09-28 |
2017-04-06 |
Trustees Of Dartmouth College |
Chimeric antigen receptor anti-inflammatory cells and methods of use
|
EP3858388B1
(en)
|
2015-09-28 |
2024-07-03 |
Regents of the University of Minnesota |
Chimeric antigen receptor (car) t cells as therapeutic interventions for gvhd
|
WO2017062628A1
(en)
|
2015-10-06 |
2017-04-13 |
City Of Hope |
Chimeric antigen receptors targeted to psca
|
AU2016335750B2
(en)
|
2015-10-07 |
2023-05-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
|
EP3359650A4
(en)
|
2015-10-08 |
2019-03-20 |
Innovative Cellular Therapeutics Co., Ltd. |
ACTIVATION AND EXPANSION OF T CELLS
|
EP3360961B1
(en)
*
|
2015-10-08 |
2023-11-22 |
National University Corporation Tokai National Higher Education and Research System |
Method for preparing genetically-modified t cells which express chimeric antigen receptor
|
ES2778651T3
(es)
*
|
2015-10-09 |
2020-08-11 |
Miltenyi Biotec Technology Inc |
Receptores de antígeno quimérico y métodos de uso
|
WO2017069958A2
(en)
|
2015-10-09 |
2017-04-27 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
EP3359694A4
(en)
*
|
2015-10-09 |
2019-07-17 |
Guardant Health, Inc. |
POPULATION-BASED TREATMENT TREATMENT USING CELL-FREE DNA
|
CN105153315B
(zh)
*
|
2015-10-09 |
2019-04-02 |
重庆精准生物技术有限公司 |
免疫抑制受体联合肿瘤抗原嵌合受体及其应用
|
CN105924530B
(zh)
*
|
2015-10-13 |
2019-08-06 |
中国人民解放军总医院 |
嵌合抗原受体及其基因和重组表达载体、car20-nkt细胞及其制备方法和应用
|
CN106755023A
(zh)
*
|
2015-10-15 |
2017-05-31 |
中国人民解放军军事医学科学院附属医院 |
带安全开关的嵌合抗原受体免疫细胞及其制备方法与应用
|
IL258491B2
(en)
|
2015-10-16 |
2023-09-01 |
Univ Columbia |
Preparations and methods for inhibiting antigens of a particular lineage
|
EP3362569B1
(en)
|
2015-10-16 |
2021-09-01 |
Ludwig-Maximilians-Universität München |
Cxcr6-transduced t cells for targeted tumor therapy
|
KR20180066237A
(ko)
|
2015-10-19 |
2018-06-18 |
유니버시티 오브 매사추세츠 |
항-암 및 항-염증 치료제 및 이의 방법
|
IL305306A
(en)
|
2015-10-20 |
2023-10-01 |
Us Health |
Methods of preparing T cells for T cell therapy
|
MA45488A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés, kits et appareil de culture de cellules
|
NZ741861A
(en)
|
2015-10-22 |
2024-02-23 |
Juno Therapeutics Gmbh |
Methods, kits, agents and apparatuses for transduction
|
MA45489A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés de culture de cellules, kits et appareil associés
|
CN105132445B
(zh)
*
|
2015-10-23 |
2018-10-02 |
马健颖 |
一种特异识别肿瘤细胞的受体蛋白、t淋巴细胞及nk细胞
|
AU2016341321A1
(en)
*
|
2015-10-23 |
2018-06-07 |
Sorrento Therapeutics, Inc. |
Programmable universal cell receptors and methods of using the same
|
WO2017075147A1
(en)
|
2015-10-27 |
2017-05-04 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor molecules and uses thereof
|
EP3368689B1
(en)
|
2015-10-28 |
2020-06-17 |
The Broad Institute, Inc. |
Composition for modulating immune responses by use of immune cell gene signature
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
US11020429B2
(en)
|
2015-11-05 |
2021-06-01 |
Juno Therapeutics, Inc. |
Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
|
MA44314A
(fr)
*
|
2015-11-05 |
2018-09-12 |
Juno Therapeutics Inc |
Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
|
EP3373969A4
(en)
|
2015-11-12 |
2019-08-14 |
Siamab Therapeutics, Inc. |
GLYCANINTERAGING COMPOUNDS AND METHOD OF USE
|
CN105331585A
(zh)
*
|
2015-11-13 |
2016-02-17 |
科济生物医药(上海)有限公司 |
携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
|
CN105384826A
(zh)
*
|
2015-11-19 |
2016-03-09 |
广州熙帝生物科技有限公司 |
表达嵌合抗原受体的脐血有核细胞及其应用
|
AU2016355178B9
(en)
|
2015-11-19 |
2019-05-30 |
Massachusetts Institute Of Technology |
Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
|
US11400145B2
(en)
*
|
2015-11-27 |
2022-08-02 |
Cartherics Pty. Ltd. |
Genetically modified cells and uses thereof
|
EP3383419B1
(en)
|
2015-12-03 |
2022-08-03 |
Juno Therapeutics, Inc. |
Compositions and methods for reducing immune responses against chimeric antigen receptors
|
EP3383892B1
(en)
|
2015-12-03 |
2022-12-21 |
Juno Therapeutics, Inc. |
Modified chimeric receptors and related compositions and methods
|
EP4012415A3
(en)
|
2015-12-04 |
2022-12-07 |
Juno Therapeutics, Inc. |
Methods and compositions related to toxicity associated with cell therapy
|
BR112018011089A2
(pt)
|
2015-12-04 |
2018-12-04 |
Intellia Therapeutics Inc |
composições e métodos para a imuno-oncologia
|
EP3384013A4
(en)
*
|
2015-12-04 |
2019-07-10 |
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. |
T-CELLS SPECIFIC TO ANTIGEN TO INDUCE IMMUNE TOLERANCE
|
US11479755B2
(en)
|
2015-12-07 |
2022-10-25 |
2Seventy Bio, Inc. |
T cell compositions
|
WO2017106332A1
(en)
|
2015-12-14 |
2017-06-22 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
JP6864296B2
(ja)
|
2015-12-14 |
2021-04-28 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
がんを処置する方法
|
DK3393468T3
(da)
|
2015-12-22 |
2022-12-19 |
X4 Pharmaceuticals Inc |
Fremgangsmåder til behandling af en immundefektsygdom
|
JP7082055B2
(ja)
|
2015-12-22 |
2022-06-07 |
ノバルティス アーゲー |
抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体(car)およびpd-l1阻害剤に対する抗体
|
CA3009709A1
(en)
|
2015-12-30 |
2017-07-06 |
Novartis Ag |
Immune effector cell therapies with enhanced efficacy
|
GB201600328D0
(en)
|
2016-01-08 |
2016-02-24 |
Univ Oslo Hf |
Anti-CD37 chimeric antigen receptors and immune cells expressing them
|
CA3004491A1
(en)
|
2016-01-08 |
2017-07-13 |
The Regents Of The University Of California |
Conditionally active heterodimeric polypeptides and methods of use thereof
|
CN105950645A
(zh)
*
|
2016-01-11 |
2016-09-21 |
灏灵赛奥(天津)生物科技有限公司 |
Car-cd19抗原受体的人源化融合基因片段、其构建方法及应用
|
US11505599B2
(en)
|
2016-01-14 |
2022-11-22 |
Memorial Sloan-Kettering Cancer Center |
T cell receptor-like antibodies specific for Foxp3-derived peptides
|
WO2017123911A1
(en)
*
|
2016-01-15 |
2017-07-20 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for treating cancer
|
WO2017125831A1
(en)
|
2016-01-21 |
2017-07-27 |
Pfizer Inc. |
Mono and bispecific antibodies for epidermal growth factor receptor variant iii and cd3 and their uses
|
CN108699124A
(zh)
|
2016-01-21 |
2018-10-23 |
辉瑞大药厂 |
靶向表皮生长因子受体变体iii的嵌合抗原受体
|
CN105567640A
(zh)
*
|
2016-01-27 |
2016-05-11 |
苏州佰通生物科技有限公司 |
一种嵌合抗原受体脂肪干细胞及其制备方法
|
BR112018016986A2
(pt)
|
2016-02-23 |
2019-02-05 |
Immune Design Corp |
preparações de vetor retroviral multigenômico e métodos e sistemas para preparação e uso das mesmas
|
US11542486B2
(en)
|
2016-03-02 |
2023-01-03 |
Board Of Regents, The University Of Texas System |
Human kynureninase enzyme variants having improved pharmacological properties
|
CA3016287A1
(en)
|
2016-03-04 |
2017-09-08 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
EP3430130B1
(en)
*
|
2016-03-14 |
2023-01-04 |
Wisconsin Alumni Research Foundation |
Methods of t cell expansion and activation
|
EP3430549A1
(en)
|
2016-03-16 |
2019-01-23 |
Juno Therapeutics, Inc. |
Methods for adaptive design of a treatment regimen and related treatments
|
WO2017161208A1
(en)
|
2016-03-16 |
2017-09-21 |
Juno Therapeutics, Inc. |
Methods for determining dosing of a therapeutic agent and related treatments
|
AU2017235116B2
(en)
|
2016-03-17 |
2019-11-07 |
Yamaguchi University |
Immunocompetent cell and expression vector expressing regulatory factors of immune function
|
CA3015369A1
(en)
|
2016-03-18 |
2017-09-21 |
Oliver Press |
Compositions and methods for cd20 immunotherapy
|
AU2017238218B2
(en)
|
2016-03-22 |
2024-05-02 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Early intervention methods to prevent or ameliorate toxicity
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
EP3436059B1
(en)
|
2016-04-01 |
2022-01-12 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Use of chimeric antigen receptor modified cells to treat cancer
|
NZ746700A
(en)
|
2016-04-01 |
2023-04-28 |
Kite Pharma Inc |
Bcma binding molecules and methods of use thereof
|
MX2018012017A
(es)
|
2016-04-01 |
2019-07-04 |
Kite Pharma Inc |
Antigeno quimerico y receptores de celulas t y metodos de uso.
|
IL296966A
(en)
|
2016-04-01 |
2022-12-01 |
Amgen Inc |
Chimeric flt-3 receptors and methods of using them
|
CA3019650C
(en)
|
2016-04-01 |
2023-07-25 |
Kite Pharma, Inc. |
Chimeric receptors and methods of use thereof
|
US10654934B2
(en)
|
2016-04-01 |
2020-05-19 |
Innovative Cellular Therapeutics CO., LTD. |
Use of chimeric antigen receptor modified cells to treat cancer
|
WO2017177230A1
(en)
|
2016-04-08 |
2017-10-12 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
ES2957890T3
(es)
|
2016-04-08 |
2024-01-29 |
Univ Emory |
Métodos de tratamiento del cáncer y las enfermedades infecciosas mediante terapias celulares
|
EP3443001A4
(en)
|
2016-04-11 |
2020-04-29 |
Obsidian Therapeutics, Inc. |
REGULATED BIOCIRCUIT SYSTEMS
|
CN106399255B
(zh)
*
|
2016-04-13 |
2019-10-18 |
阿思科力(苏州)生物科技有限公司 |
Pd-1 car-t细胞及其制备方法和应用
|
US10188749B2
(en)
|
2016-04-14 |
2019-01-29 |
Fred Hutchinson Cancer Research Center |
Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
|
IL310729A
(en)
|
2016-04-15 |
2024-04-01 |
Alpine Immune Sciences Inc |
Immunomodulatory proteins that are variants of CD80 and their uses
|
KR20220133318A
(ko)
|
2016-04-15 |
2022-10-04 |
노파르티스 아게 |
선택적 단백질 발현을 위한 조성물 및 방법
|
US20190346442A1
(en)
|
2016-04-18 |
2019-11-14 |
The Broad Institute, Inc. |
Improved hla epitope prediction
|
CN105907719B
(zh)
*
|
2016-04-18 |
2019-10-18 |
阿思科力(苏州)生物科技有限公司 |
Anti ROBO1 CAR-T细胞及其制备和应用
|
WO2018018958A1
(en)
*
|
2016-04-22 |
2018-02-01 |
Carsgen Therapeutics Co., Ltd. |
Compositions and methods of cellular immunotherapy
|
WO2017192536A1
(en)
|
2016-05-02 |
2017-11-09 |
University Of Kansas |
Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
|
MA44869A
(fr)
|
2016-05-06 |
2019-03-13 |
Editas Medicine Inc |
Cellules génétiquement modifiées et leurs procédés de fabrication
|
WO2017195153A1
(en)
*
|
2016-05-11 |
2017-11-16 |
The University Of Chicago |
Methods of treating cancers with ct45 targeted therapies
|
CA3025516A1
(en)
*
|
2016-05-27 |
2017-11-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Flt3-specific chimeric antigen receptors and methods using same
|
AU2017268842B2
(en)
|
2016-05-27 |
2022-08-11 |
Aadigen, Llc |
Peptides and nanoparticles for intracellular delivery of genome-editing molecules
|
CN105837693A
(zh)
*
|
2016-05-30 |
2016-08-10 |
李斯文 |
一种基于bcma的抗原嵌合受体及其制备方法和应用
|
US20210177896A1
(en)
|
2016-06-02 |
2021-06-17 |
Novartis Ag |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
JP2019517518A
(ja)
|
2016-06-03 |
2019-06-24 |
メモリアル スローン ケタリング キャンサー センター |
早期治療選択肢としての養子細胞療法
|
GB201609811D0
(en)
|
2016-06-05 |
2016-07-20 |
Snipr Technologies Ltd |
Methods, cells, systems, arrays, RNA and kits
|
US11390658B2
(en)
|
2016-06-06 |
2022-07-19 |
St. Jude Children's Research Hospital |
Anti-CD7 chimeric antigen receptor and method of use thereof
|
MA45341A
(fr)
|
2016-06-06 |
2019-04-10 |
Hutchinson Fred Cancer Res |
Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
|
CN109641962A
(zh)
|
2016-06-08 |
2019-04-16 |
艾伯维公司 |
抗b7-h3抗体和抗体药物偶联物
|
CA3027033A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
CA3027044A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
CA3027047A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
CA3027046A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
TWI762487B
(zh)
|
2016-06-08 |
2022-05-01 |
美商艾伯維有限公司 |
抗-b7-h3抗體及抗體藥物結合物
|
KR102469703B1
(ko)
*
|
2016-06-08 |
2022-11-23 |
프레시전 인코포레이티드 |
Cd33 특이적 키메라 항원 수용체
|
EP3471727B1
(en)
|
2016-06-21 |
2020-12-09 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
JP7084624B2
(ja)
|
2016-06-21 |
2022-06-15 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
Cxcr4阻害剤およびその使用
|
CN109641838A
(zh)
|
2016-06-21 |
2019-04-16 |
X4 制药有限公司 |
Cxcr4抑制剂及其用途
|
CN106117367B
(zh)
*
|
2016-06-24 |
2020-02-11 |
安徽未名细胞治疗有限公司 |
一种her-3特异性嵌合抗原受体及其应用
|
MA45491A
(fr)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
|
MA45455A
(fr)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
Procédé d'identification d'épitopes peptidiques, molécules qui se lient à de tels épitopes et utilisations associées
|
WO2018002358A1
(en)
|
2016-06-30 |
2018-01-04 |
F. Hoffmann-La Roche Ag |
Improved adoptive t-cell therapy
|
CA3030683C
(en)
|
2016-07-12 |
2023-11-21 |
Kite Pharma, Inc. |
Antigen binding molecules and methods of use thereof
|
JP2018035137A
(ja)
|
2016-07-13 |
2018-03-08 |
マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag |
新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用
|
AU2017295886C1
(en)
|
2016-07-15 |
2024-05-16 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
CN109477114A
(zh)
*
|
2016-07-18 |
2019-03-15 |
赫利克斯生物药品公司 |
治疗癌症的针对癌胚抗原相关细胞粘附分子6的car免疫细胞
|
CA3031542A1
(en)
*
|
2016-07-20 |
2018-01-25 |
University Of Utah Research Foundation |
Cd229 car t cells and methods of use thereof
|
US11384156B2
(en)
|
2016-07-25 |
2022-07-12 |
The Nemours Foundation |
Adoptive T-cell therapy using EMPD-specific chimeric antigen receptors for treating IgE-mediated allergic diseases
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
CA3032120A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
CN118021943A
(zh)
|
2016-07-28 |
2024-05-14 |
诺华股份有限公司 |
嵌合抗原受体和pd-1抑制剂的组合疗法
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
CN110088133B
(zh)
*
|
2016-07-29 |
2023-12-08 |
朱诺治疗学股份有限公司 |
抗独特型抗体及相关方法
|
WO2018023093A1
(en)
|
2016-07-29 |
2018-02-01 |
Juno Therapeutics, Inc. |
Immunomodulatory polypeptides and related compositions and methods
|
AU2017301881A1
(en)
|
2016-07-29 |
2019-02-07 |
Juno Therapeutics, Inc. |
Methods for assessing the presence or absence of replication competent virus
|
CN110267677A
(zh)
|
2016-08-01 |
2019-09-20 |
诺华股份有限公司 |
使用与原m2巨噬细胞分子抑制剂组合的嵌合抗原受体治疗癌症
|
CA3032498A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
US11078481B1
(en)
|
2016-08-03 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for screening for cancer targets
|
US11630103B2
(en)
|
2016-08-17 |
2023-04-18 |
The Broad Institute, Inc. |
Product and methods useful for modulating and evaluating immune responses
|
EP3506916B1
(en)
|
2016-09-01 |
2021-04-07 |
Chimera Bioengineering Inc. |
Gold optimized car t-cells
|
US11453712B2
(en)
|
2016-09-02 |
2022-09-27 |
Lentigen Technology Inc. |
Compositions and methods for treating cancer with DuoCARs
|
US11078483B1
(en)
|
2016-09-02 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for measuring and improving CRISPR reagent function
|
KR20190057308A
(ko)
|
2016-09-02 |
2019-05-28 |
더 리전츠 오브 더 유니버시티 오브 캘리포니아 |
인터류킨-6 수용체 알파-결합 단일 사슬 가변 단편을 포함하는 방법 및 조성물
|
WO2018049025A2
(en)
|
2016-09-07 |
2018-03-15 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses
|
MA46194A
(fr)
|
2016-09-12 |
2019-07-17 |
Juno Therapeutics Inc |
Ensembles de poches de bioréacteur de perfusion
|
JP6908710B2
(ja)
|
2016-09-21 |
2021-07-28 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
ケモカイン受容体ccr4を標的にするキメラ抗原受容体(car)およびその使用
|
WO2018057904A1
(en)
*
|
2016-09-23 |
2018-03-29 |
University Of Southern California |
Chimeric antigen receptors and compositions and methods of use thereof
|
TWI719894B
(zh)
|
2016-09-28 |
2021-02-21 |
美商凱特製藥公司 |
抗原結合分子類和使用彼等之方法
|
US20190298771A1
(en)
|
2016-09-28 |
2019-10-03 |
Atossa Genetics Inc. |
Methods of adoptive cell therapy
|
KR20190062505A
(ko)
|
2016-10-03 |
2019-06-05 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Hpv-특이적 결합 분자
|
WO2018067991A1
(en)
|
2016-10-07 |
2018-04-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
SG10201913823VA
(en)
|
2016-10-07 |
2020-03-30 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
CN109689686B
(zh)
|
2016-10-07 |
2020-08-25 |
T细胞受体治疗公司 |
使用融合蛋白进行t细胞受体重编程的组合物和方法
|
CN107151654B
(zh)
*
|
2016-10-11 |
2020-05-05 |
深圳宾德生物技术有限公司 |
一种人源t淋巴细胞的培养基及其制备方法和应用
|
BR112019006652A2
(pt)
|
2016-10-13 |
2019-07-02 |
Juno Therapeutics Inc |
métodos e composições para imunoterapia envolvendo moduladores da via metabólica do triptofano
|
CN107936120B
(zh)
*
|
2016-10-13 |
2021-03-09 |
上海赛比曼生物科技有限公司 |
Cd19靶向性的嵌合抗原受体及其制法和应用
|
CN110520530A
(zh)
|
2016-10-18 |
2019-11-29 |
明尼苏达大学董事会 |
肿瘤浸润性淋巴细胞和治疗方法
|
WO2018075807A1
(en)
|
2016-10-19 |
2018-04-26 |
California Institute For Biomedical Research |
Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
|
ES2916335T3
(es)
|
2016-10-20 |
2022-06-30 |
Celgene Corp |
Receptores de antígeno quimérico heterodimerizable basados en cereblon
|
WO2018075978A1
(en)
|
2016-10-20 |
2018-04-26 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
MA46716A
(fr)
|
2016-11-03 |
2019-09-11 |
Juno Therapeutics Inc |
Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie
|
CA3042049A1
(en)
|
2016-11-03 |
2018-05-11 |
Juno Therapeutics, Inc. |
Combination therapy of a t cell therapy and a btk inhibitor
|
US11332713B2
(en)
|
2016-11-16 |
2022-05-17 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
US11401330B2
(en)
|
2016-11-17 |
2022-08-02 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
AU2017363278B2
(en)
*
|
2016-11-22 |
2022-10-27 |
National University Of Singapore |
Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
|
US11851491B2
(en)
|
2016-11-22 |
2023-12-26 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
CN110114070A
(zh)
|
2016-11-23 |
2019-08-09 |
诺华公司 |
使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法
|
US20190030073A1
(en)
*
|
2016-12-02 |
2019-01-31 |
Cartesian Therapeutics, Inc. |
Cancer immunotherapy with highly enriched cd8+ chimeric antigen receptor t cells
|
ES2961666T3
(es)
|
2016-12-03 |
2024-03-13 |
Juno Therapeutics Inc |
Métodos para determinar la dosificación de células CAR-T
|
CN110545826A
(zh)
|
2016-12-03 |
2019-12-06 |
朱诺治疗学股份有限公司 |
用于与激酶抑制剂组合使用治疗性t细胞的方法和组合物
|
BR112019011025A2
(pt)
|
2016-12-03 |
2019-10-08 |
Juno Therapeutics Inc |
métodos para modulação de células t car
|
CA3045338A1
(en)
|
2016-12-05 |
2018-06-14 |
Juno Therapeutics, Inc. |
Production of engineered cells for adoptive cell therapy
|
CN108165568B
(zh)
*
|
2016-12-07 |
2020-12-08 |
上海恒润达生生物科技有限公司 |
一种培养CD19CAR-iNKT细胞方法及用途
|
CN107058315B
(zh)
*
|
2016-12-08 |
2019-11-08 |
上海优卡迪生物医药科技有限公司 |
敲减人PD-1的siRNA、重组表达CAR-T载体及其构建方法和应用
|
WO2018111763A1
(en)
|
2016-12-12 |
2018-06-21 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
|
CN108218994A
(zh)
*
|
2016-12-14 |
2018-06-29 |
上海恒润达生生物科技有限公司 |
一种方法培养t记忆干细胞
|
US11111483B2
(en)
|
2016-12-16 |
2021-09-07 |
B-Mogen Biotechnologies, Inc. |
Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems and methods
|
US11278570B2
(en)
|
2016-12-16 |
2022-03-22 |
B-Mogen Biotechnologies, Inc. |
Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
|
CN108276493B
(zh)
*
|
2016-12-30 |
2023-11-14 |
南京传奇生物科技有限公司 |
一种嵌合抗原受体及其应用
|
CA3048312A1
(en)
|
2017-01-01 |
2018-07-05 |
Chi-Yu Gregory Lee |
Rp215 chimeric antigen receptor construct and methods of making and using same
|
CN110248677B
(zh)
|
2017-01-05 |
2023-05-16 |
上海煦顼技术有限公司 |
人源化抗cd19抗体及其与嵌合抗原受体的用途
|
CA3049244A1
(en)
|
2017-01-05 |
2018-07-12 |
Fred Hutchinson Cancer Research Center |
Systems and methods to improve vaccine efficacy
|
CA3049165A1
(en)
|
2017-01-06 |
2018-07-12 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
TW201837168A
(zh)
|
2017-01-06 |
2018-10-16 |
美商艾歐凡斯生物治療公司 |
以腫瘤壞死因子受體超家族(tnfrsf)促效劑使腫瘤浸潤淋巴球(til)擴增及til與tnfrsf促效劑的治療組合
|
EP3565638B8
(en)
|
2017-01-06 |
2024-04-10 |
BicycleRD Limited |
Bicycle conjugate for treating cancer
|
EP3346001A1
(en)
*
|
2017-01-06 |
2018-07-11 |
TXCell |
Monospecific regulatory t cell population with cytotoxicity for b cells
|
CN108285920A
(zh)
*
|
2017-01-09 |
2018-07-17 |
上海恒润达生生物科技有限公司 |
一种体内检测cart细胞表达的技术及其用途
|
MX2019008227A
(es)
|
2017-01-10 |
2020-08-17 |
Juno Therapeutics Inc |
Analisis epigenetico de terapia celular y metodos relacionados.
|
GB201700553D0
(en)
|
2017-01-12 |
2017-03-01 |
Genagon Therapeutics Ab |
Therapeutic agents
|
JP7303749B2
(ja)
*
|
2017-01-13 |
2023-07-05 |
セルダラ メディカル、エルエルシー |
Tim-1を標的とするキメラ抗原受容体
|
MX2019008538A
(es)
|
2017-01-20 |
2019-11-05 |
Juno Therapeutics Gmbh |
Conjugados de superficie celular y composiciones y métodos celulares relacionados.
|
WO2018140391A1
(en)
|
2017-01-24 |
2018-08-02 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
CN108342363B
(zh)
*
|
2017-01-25 |
2021-02-12 |
北京马力喏生物科技有限公司 |
共表达抗msln嵌合抗原受体和免疫检查点抑制分子的转基因淋巴细胞及其用途
|
EP3574005B1
(en)
|
2017-01-26 |
2021-12-15 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
RU2674894C2
(ru)
*
|
2017-01-30 |
2018-12-13 |
Общество с ограниченной ответственностью "ПЛАНТА" |
Новые люциферазы и способы их использования
|
WO2018144597A1
(en)
*
|
2017-01-31 |
2018-08-09 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Methods of sensitizing cancer cells to immune cell killing
|
WO2018144535A1
(en)
|
2017-01-31 |
2018-08-09 |
Novartis Ag |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
WO2018148224A1
(en)
|
2017-02-07 |
2018-08-16 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
|
JP7370861B2
(ja)
|
2017-02-12 |
2023-10-30 |
ビオンテック ユーエス インコーポレイテッド |
Hlaに基づく方法および組成物ならびにそれらの使用
|
ES2900233T3
(es)
|
2017-02-14 |
2022-03-16 |
Kite Pharma Inc |
Moléculas que se unen a CD70 y métodos de uso de las mismas
|
JP2020507605A
(ja)
|
2017-02-17 |
2020-03-12 |
フレッド ハッチンソン キャンサー リサーチ センター |
Bcma関連癌および自己免疫疾患の治療のための併用療法
|
EP3585880A1
(en)
|
2017-02-27 |
2020-01-01 |
Life Technologies Corporation |
Expansion of populations of t cells by the use of modified serum free media
|
AU2018224856A1
(en)
|
2017-02-27 |
2019-08-29 |
Juno Therapeutics, Inc. |
Compositions, articles of manufacture and methods related to dosing in cell therapy
|
US20200048359A1
(en)
|
2017-02-28 |
2020-02-13 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
EP3589295A4
(en)
|
2017-02-28 |
2020-11-04 |
Endocyte, Inc. |
COMPOSITIONS AND METHODS OF T CAR LYMPHOCYTE THERAPY
|
US11629340B2
(en)
|
2017-03-03 |
2023-04-18 |
Obsidian Therapeutics, Inc. |
DHFR tunable protein regulation
|
JP2020510671A
(ja)
|
2017-03-03 |
2020-04-09 |
シアトル ジェネティックス, インコーポレイテッド |
グリカン相互作用化合物および使用の方法
|
CA3055202A1
(en)
*
|
2017-03-03 |
2018-09-07 |
Obsidian Therapeutics, Inc. |
Cd19 compositions and methods for immunotherapy
|
WO2018169922A2
(en)
|
2017-03-13 |
2018-09-20 |
Kite Pharma, Inc. |
Chimeric antigen receptors for melanoma and uses thereof
|
WO2018170188A2
(en)
|
2017-03-14 |
2018-09-20 |
Juno Therapeutics, Inc. |
Methods for cryogenic storage
|
PL3596116T3
(pl)
|
2017-03-16 |
2024-05-13 |
Alpine Immune Sciences, Inc. |
Białka immunomodulujące wariant Pd-l1 i ich zastosowania
|
WO2018170023A1
(en)
|
2017-03-16 |
2018-09-20 |
Alpine Immune Sciences, Inc. |
Pd-l2 variant immunomodulatory proteins and uses thereof
|
JP7386083B2
(ja)
|
2017-03-16 |
2023-11-24 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
Cd80バリアント免疫調節タンパク質及びその使用
|
CN110621335A
(zh)
|
2017-03-17 |
2019-12-27 |
弗雷德哈钦森癌症研究中心 |
免疫调节融合蛋白及其用途
|
BR112019018124A2
(pt)
|
2017-03-22 |
2020-04-07 |
Intellia Therapeutics Inc |
composições e métodos para imunooncologia
|
EP3600395A4
(en)
|
2017-03-23 |
2021-05-05 |
The General Hospital Corporation |
BLOCKING OF CXCR4 / CXCR7 AND TREATMENT OF HUMAN PAPILLOMAVIRUS-ASSOCIATED DISEASE
|
CA3057838A1
(en)
|
2017-03-24 |
2018-09-27 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd33 immunotherapy
|
JP7270253B2
(ja)
|
2017-03-27 |
2023-05-10 |
ナショナル ユニヴァーシティ オブ シンガポール |
ナチュラルキラー細胞のエクスビボ拡大及び活性化のための刺激細胞株
|
KR102660336B1
(ko)
|
2017-03-27 |
2024-04-26 |
내셔널 유니버시티 오브 싱가포르 |
절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도
|
WO2018183888A2
(en)
|
2017-03-31 |
2018-10-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
|
WO2018183908A1
(en)
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
US11913075B2
(en)
|
2017-04-01 |
2024-02-27 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
MX2019011679A
(es)
|
2017-04-01 |
2019-11-01 |
Avm Biotechnology Llc |
Reemplazo de un pre-acondicionamiento citotoxico antes de una inmunoterapia celular.
|
AR111360A1
(es)
|
2017-04-03 |
2019-07-03 |
Kite Pharma Inc |
Tratamiento usando células t de receptor quimérico incorporando células t polifuncionales optimizadas
|
EP3607319A1
(en)
|
2017-04-07 |
2020-02-12 |
Juno Therapeutics, Inc. |
Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
|
US20200071773A1
(en)
|
2017-04-12 |
2020-03-05 |
Massachusetts Eye And Ear Infirmary |
Tumor signature for metastasis, compositions of matter methods of use thereof
|
MA54103A
(fr)
|
2017-04-14 |
2021-09-15 |
Juno Therapeutics Inc |
Procédés d'évaluation de la glycosylation de surface cellulaire
|
AU2018251187B2
(en)
|
2017-04-14 |
2024-03-28 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for transient gene therapy with enhanced stability
|
CN108727497A
(zh)
*
|
2017-04-17 |
2018-11-02 |
沈阳美达博生物科技有限公司 |
一种cd19抗体及其应用
|
WO2018195019A1
(en)
|
2017-04-18 |
2018-10-25 |
The Broad Institute Inc. |
Compositions for detecting secretion and methods of use
|
EA201992469A1
(ru)
|
2017-04-18 |
2020-05-27 |
Фуджифилм Селльюлар Дайнамикс, Инк. |
Антигенспецифические иммунные эффекторные клетки
|
US11344578B2
(en)
|
2017-04-19 |
2022-05-31 |
Board Of Regents, The University Of Texas System |
Immune cells expressing engineered antigen receptors
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
CA3059939A1
(en)
|
2017-04-21 |
2018-10-25 |
Kyn Therapeutics |
Indole ahr inhibitors and uses thereof
|
JOP20180042A1
(ar)
|
2017-04-24 |
2019-01-30 |
Kite Pharma Inc |
نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
|
AR111625A1
(es)
|
2017-04-27 |
2019-07-31 |
Juno Therapeutics Gmbh |
Reactivos de partículas oligoméricas y métodos de uso de los mismos
|
US20200055948A1
(en)
|
2017-04-28 |
2020-02-20 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
JP7299841B2
(ja)
|
2017-05-01 |
2023-06-28 |
ジュノー セラピューティクス インコーポレイテッド |
細胞療法と免疫調節化合物の併用
|
CN107226867B
(zh)
*
|
2017-07-25 |
2018-02-06 |
重庆精准生物技术有限公司 |
抗人cd19抗原的嵌合抗原受体及其应用
|
DE112018002302B4
(de)
*
|
2017-05-02 |
2020-10-22 |
Chongqing Precision Biotech Company Limited |
Chimärer Antigenrezeptor von Anti-Human-CD19-Antigen und dessen Anwendung
|
US20200224161A1
(en)
*
|
2017-05-10 |
2020-07-16 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
US20180325955A1
(en)
|
2017-05-12 |
2018-11-15 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
JP2020519298A
(ja)
|
2017-05-15 |
2020-07-02 |
アメリカ合衆国 |
バイシストロン性キメラ抗原受容体及びそれらの使用
|
US10415017B2
(en)
|
2017-05-17 |
2019-09-17 |
Thunder Biotech, Inc. |
Transgenic macrophages, chimeric antigen receptors, and associated methods
|
US11576933B2
(en)
|
2017-05-24 |
2023-02-14 |
Effector Therapeutics Inc. |
Compositions and methods for an improved antitumor immune response
|
EP3406733A1
(en)
|
2017-05-24 |
2018-11-28 |
SIB Swiss Institute of Bioinformatics |
Kinase mutants and uses thereof
|
US11033622B2
(en)
|
2017-05-25 |
2021-06-15 |
Leidos, Inc. |
PD-1 and CTLA-4 dual inhibitor peptides
|
CN110662831A
(zh)
|
2017-05-26 |
2020-01-07 |
凯德药业股份有限公司 |
制备和使用胚胎间充质祖细胞的方法
|
WO2018219278A1
(en)
|
2017-06-01 |
2018-12-06 |
Innovative Cellular Therapeutics CO., LTD. |
Chimeric antigen receptor cell preparation and uses thereof
|
US11413310B2
(en)
|
2017-06-02 |
2022-08-16 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
MX2019014288A
(es)
|
2017-06-02 |
2020-08-03 |
Juno Therapeutics Inc |
Articulos de manufactura y metodos relacionados a toxicidad asociada con terapia celular.
|
EP3631805A4
(en)
*
|
2017-06-02 |
2021-03-24 |
Mayo Foundation for Medical Education and Research |
SYSTEM AND METHOD FOR PROVIDING EXPERTISE FROM CLINICAL RESULTS IN DISEASE TREATMENT
|
WO2018232195A1
(en)
|
2017-06-14 |
2018-12-20 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
ES2871400T3
(es)
|
2017-06-20 |
2021-10-28 |
Inst Nat Sante Rech Med |
Células inmunitarias deficientes en SUV39H1
|
EP3642344A4
(en)
|
2017-06-21 |
2021-03-31 |
The University of North Carolina at Chapel Hill |
PROCEDURES AND COMPOSITIONS FOR CANCER CELL TARGETING CHIMERIC ANTIGEN RECEPTORS
|
KR20200019231A
(ko)
|
2017-06-22 |
2020-02-21 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
조절 면역 세포를 제조하기 위한 방법 및 이의 용도
|
CA3066774A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
|
CA3066779A1
(en)
|
2017-06-28 |
2019-01-03 |
Regeneron Pharmaceuticals, Inc. |
Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereof
|
CA3067602A1
(en)
|
2017-06-29 |
2019-01-03 |
Juno Therapeutics, Inc. |
Mouse model for assessing toxicities associated with immunotherapies
|
US11235004B2
(en)
|
2017-06-30 |
2022-02-01 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Lymphocyte cell lines and uses thereof
|
EP3645021A4
(en)
|
2017-06-30 |
2021-04-21 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
CA3067914A1
(en)
|
2017-06-30 |
2019-01-03 |
Cellectis |
Cellular immunotherapy for repetitive administration
|
CN107287164A
(zh)
*
|
2017-07-07 |
2017-10-24 |
青岛协和华美医学诊断技术有限公司 |
靶向cd19的嵌合抗原受体t细胞、制备方法及应用
|
CN107365798B
(zh)
*
|
2017-07-13 |
2020-07-14 |
山东省齐鲁细胞治疗工程技术有限公司 |
一种携带iCasp9***基因的CD19-CAR-T细胞及其应用
|
KR20200028447A
(ko)
|
2017-07-17 |
2020-03-16 |
얀센 바이오테크 인코포레이티드 |
피브로넥틴 iii형 도메인에 대한 항원 결합 영역 및 이의 사용 방법
|
EP3661528A1
(en)
|
2017-07-29 |
2020-06-10 |
Juno Therapeutics, Inc. |
Reagents for expanding cells expressing recombinant receptors
|
CA3071624A1
(en)
|
2017-07-31 |
2019-02-07 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapy
|
WO2019067092A1
(en)
|
2017-08-07 |
2019-04-04 |
The Johns Hopkins University |
METHODS AND SUBSTANCES FOR THE EVALUATION AND TREATMENT OF CANCER
|
AU2018313950A1
(en)
|
2017-08-09 |
2020-02-13 |
Juno Therapeutics, Inc. |
Methods for producing genetically engineered cell compositions and related compositions
|
BR112020001601A2
(pt)
|
2017-08-09 |
2020-08-11 |
Juno Therapeutics Inc |
métodos e composições para preparar células geneticamente manipuladas
|
CA3071282A1
(en)
|
2017-08-10 |
2019-02-14 |
National University Of Singapore |
T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
|
AU2018319016B2
(en)
|
2017-08-17 |
2023-08-31 |
Ikena Oncology, Inc. |
AHR inhibitors and uses thereof
|
MA50057A
(fr)
|
2017-09-01 |
2020-07-08 |
Juno Therapeutics Inc |
Expression génique et évaluation d'un risque de développement d'une toxicité suite à une thérapie cellulaire
|
EP3675876A4
(en)
|
2017-09-01 |
2021-06-02 |
GPB Scientific, Inc. |
PROCESSES FOR PREPARING THERAPEUTICALLY ACTIVE CELLS USING MICROFLUIDICS
|
EP3679370A1
(en)
|
2017-09-07 |
2020-07-15 |
Juno Therapeutics, Inc. |
Methods of identifying cellular attributes related to outcomes associated with cell therapy
|
CN107557337B
(zh)
*
|
2017-09-15 |
2020-06-26 |
山东兴瑞生物科技有限公司 |
一种抗ror1安全型嵌合抗原受体修饰的免疫细胞及其应用
|
KR102521245B1
(ko)
|
2017-09-15 |
2023-04-17 |
카이트 파마 인코포레이티드 |
관리 연속성 및 신원 연속성 생물학적 샘플 추적으로 환자-특이적 면역요법 절차를 수행하기 위한 방법 및 시스템
|
JP2020533986A
(ja)
|
2017-09-15 |
2020-11-26 |
ライフ テクノロジーズ コーポレーション |
細胞を培養および増殖させるための組成物および方法
|
AU2018338418A1
(en)
*
|
2017-09-19 |
2020-04-09 |
Cdrd Ventures Inc. |
Anti-HLA-A2 antibodies and methods of using the same
|
CA3076337A1
(en)
|
2017-09-19 |
2019-03-28 |
Massachusetts Institute Of Technology |
Compositions for chimeric antigen receptor t cell therapy and uses thereof
|
CN109517820B
(zh)
|
2017-09-20 |
2021-09-24 |
北京宇繁生物科技有限公司 |
一种靶向HPK1的gRNA以及HPK1基因编辑方法
|
EP3684822A4
(en)
|
2017-09-20 |
2021-06-16 |
The University of British Columbia |
NEW ANTI-HLA-A2 ANTIBODIES AND USES THEREOF
|
CN111511388A
(zh)
|
2017-09-21 |
2020-08-07 |
博德研究所 |
用于靶向核酸编辑的***、方法和组合物
|
EP3684803A1
(en)
|
2017-09-22 |
2020-07-29 |
Kite Pharma, Inc. |
Antigen binding molecules and methods of use thereof
|
IL295603B2
(en)
|
2017-09-22 |
2024-03-01 |
Kymera Therapeutics Inc |
Protein compounds and their uses
|
SG11202002533QA
(en)
|
2017-09-22 |
2020-04-29 |
Kite Pharma Inc |
Chimeric polypeptides and uses thereof
|
US11358948B2
(en)
|
2017-09-22 |
2022-06-14 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
CN111433354A
(zh)
*
|
2017-09-26 |
2020-07-17 |
朗沃德大学 |
作为免疫疗法的pd1特异性嵌合抗原受体
|
CN109554349B
(zh)
*
|
2017-09-27 |
2022-06-24 |
亘喜生物科技(上海)有限公司 |
Pd-1基因表达沉默的工程化免疫细胞
|
TWI731268B
(zh)
*
|
2017-09-29 |
2021-06-21 |
財團法人國家衛生研究院 |
可增強抗腫瘤與抗病毒t細胞存活與其功能性之方法與組合物
|
MX2020003536A
(es)
|
2017-10-03 |
2020-09-14 |
Juno Therapeutics Inc |
Moleculas de union especifica a virus de papiloma humano (hpv).
|
WO2019074892A1
(en)
|
2017-10-09 |
2019-04-18 |
Wisconsin Alumni Research Foundation |
ANTIBODIES TARGETING GLIOBLASTOME STRAIN TYPE CELLS AND METHODS OF USE
|
KR20200074137A
(ko)
|
2017-10-10 |
2020-06-24 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Ctla-4 변이체 면역조절 단백질 및 이의 용도
|
US20190151361A1
(en)
|
2017-10-18 |
2019-05-23 |
Kite Pharma, Inc. |
Methods of administering chimeric antigen receptor immunotherapy
|
CN111629749A
(zh)
|
2017-10-18 |
2020-09-04 |
诺华股份有限公司 |
用于选择性蛋白质降解的组合物和方法
|
CA3078517A1
(en)
|
2017-10-18 |
2019-04-25 |
Alpine Immune Sciences, Inc. |
Variant icos ligand immunomodulatory proteins and related compositions and methods
|
CN109694854B
(zh)
*
|
2017-10-20 |
2023-11-21 |
亘喜生物科技(上海)有限公司 |
通用型嵌合抗原受体t细胞制备技术
|
US11732257B2
(en)
|
2017-10-23 |
2023-08-22 |
Massachusetts Institute Of Technology |
Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries
|
WO2019084234A1
(en)
*
|
2017-10-26 |
2019-05-02 |
St. Jude Childen's Research Hospital, Inc. |
METHODS AND COMPOSITIONS FOR TREATING CD33 + CANCERS AND IMPROVING IN VIVO PERSISTENCE OF CHIMERIC ANTIGEN RECEPTOR T CELLS
|
WO2019084427A1
(en)
|
2017-10-27 |
2019-05-02 |
Kite Pharma, Inc. |
T-LYMPHOCYTE RECEPTOR ANTIGEN BINDING MOLECULES AND METHODS OF USE THEREOF
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
WO2019089969A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
BR112020008638A2
(pt)
|
2017-11-01 |
2020-10-20 |
Juno Therapeutics Inc |
receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma)
|
MX2020004608A
(es)
|
2017-11-01 |
2020-10-05 |
Editas Medicine Inc |
Metodos, composiciones y componentes para edicion crispr-cas9 de tgfbr2 en celulas t para inmunoterapia.
|
SG11202003657VA
(en)
|
2017-11-01 |
2020-05-28 |
Juno Therapeutics Inc |
Process for producing a t cell composition
|
MA50855A
(fr)
|
2017-11-01 |
2020-09-09 |
Juno Therapeutics Inc |
Procédé de génération de compositions thérapeutiques de cellules modifiées
|
US11564946B2
(en)
|
2017-11-01 |
2023-01-31 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
US11851679B2
(en)
|
2017-11-01 |
2023-12-26 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
US10428141B2
(en)
*
|
2017-11-03 |
2019-10-01 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-ROR1 immunotherapy
|
WO2019090202A1
(en)
|
2017-11-06 |
2019-05-09 |
Editas Medicine, Inc. |
Methods, compositions and components for crispr-cas9 editing of cblb in t cells for immunotherapy
|
MX2020004568A
(es)
|
2017-11-06 |
2020-10-05 |
Juno Therapeutics Inc |
Combinación de una terapia celular y un inhibidor de gamma secretasa.
|
CA3079999A1
(en)
*
|
2017-11-07 |
2019-05-16 |
The Board Of Regents Of The University Of Texas System |
Targeting lilrb4 with car-t or car-nk cells in the treatment of cancer
|
MA50571A
(fr)
|
2017-11-10 |
2020-09-16 |
Juno Therapeutics Inc |
Réservoirs cryogéniques à système fermé
|
WO2019094482A1
(en)
|
2017-11-10 |
2019-05-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors targeting tumor antigens
|
EP3710039A4
(en)
|
2017-11-13 |
2021-08-04 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR CANCER TREATMENT BY TARGETING THE CLEC2D-KLRB1 PATH
|
WO2019099433A2
(en)
|
2017-11-14 |
2019-05-23 |
Arcellx, Inc. |
D-domain containing polypeptides and uses thereof
|
KR20200087176A
(ko)
|
2017-11-14 |
2020-07-20 |
아르셀엑스, 인크. |
다기능성 면역 세포 요법
|
JP2021502979A
(ja)
|
2017-11-15 |
2021-02-04 |
ノバルティス アーゲー |
Bcmaターゲティングキメラ抗原受容体、cd19ターゲティングキメラ抗原受容体及び併用療法
|
WO2019099707A1
(en)
|
2017-11-16 |
2019-05-23 |
Kite Pharma, Inc |
Modified chimeric antigen receptors and methods of use
|
JP2021503885A
(ja)
*
|
2017-11-22 |
2021-02-15 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
末梢血からの末梢血リンパ球(pbl)の拡大培養
|
CN109837244A
(zh)
*
|
2017-11-25 |
2019-06-04 |
深圳宾德生物技术有限公司 |
一种敲除pd1的靶向cd19的嵌合抗原受体t细胞及其制备方法和应用
|
AU2018375738A1
(en)
|
2017-11-30 |
2020-06-11 |
Novartis Ag |
BCMA-targeting chimeric antigen receptor, and uses thereof
|
US20210198372A1
(en)
|
2017-12-01 |
2021-07-01 |
Juno Therapeutics, Inc. |
Methods for dosing and for modulation of genetically engineered cells
|
WO2019112978A2
(en)
*
|
2017-12-04 |
2019-06-13 |
Coare Biotechnology, Inc. |
Anti-dclk1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof
|
MX2020005907A
(es)
|
2017-12-08 |
2020-10-19 |
Juno Therapeutics Inc |
Formulacion de medio libre de suero para cultivar celulas y metodos de uso de la misma.
|
SG11202005272SA
(en)
|
2017-12-08 |
2020-07-29 |
Juno Therapeutics Inc |
Process for producing a composition of engineered t cells
|
MX2020005906A
(es)
|
2017-12-08 |
2020-10-22 |
Juno Therapeutics Inc |
Marcadores fenotipicos para terapia celular y metodos relacionados.
|
US12006356B2
(en)
|
2017-12-15 |
2024-06-11 |
Juno Therapeutics, Inc. |
Anti-CCT5 binding molecules and chimeric antigen receptors comprising the same
|
US20210369775A1
(en)
|
2017-12-15 |
2021-12-02 |
Iovance Biotherapeutics, Inc. |
Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
|
US11661439B2
(en)
|
2017-12-17 |
2023-05-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Peptide hydrogels and use thereof
|
WO2019126186A1
(en)
|
2017-12-18 |
2019-06-27 |
Neon Therapeutics, Inc. |
Neoantigens and uses thereof
|
CA3084582A1
(en)
|
2017-12-20 |
2019-06-27 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
WO2019123340A1
(en)
|
2017-12-20 |
2019-06-27 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
CN108018312B
(zh)
*
|
2017-12-20 |
2019-09-10 |
上海优卡迪生物医药科技有限公司 |
一种t淋巴细胞白血病的car-t治疗载体及其构建方法和应用
|
GB201721833D0
(en)
*
|
2017-12-22 |
2018-02-07 |
Cancer Research Tech Ltd |
Fusion proteins
|
IL275649B2
(en)
|
2017-12-26 |
2023-12-01 |
Kymera Therapeutics Inc |
IRAK joints and used in them
|
CN109971712B
(zh)
*
|
2017-12-28 |
2023-06-20 |
上海细胞治疗研究院 |
特异性靶向cd19抗原且高水平稳定表达pd-1抗体的car-t细胞及用途
|
CN109970866B
(zh)
*
|
2017-12-28 |
2022-10-04 |
上海细胞治疗研究院 |
一种cd28双向激活共刺激分子受体及其用途
|
CN109970864A
(zh)
*
|
2017-12-28 |
2019-07-05 |
上海细胞治疗研究院 |
一种双向激活共刺激分子受体及其用途
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
US20190211109A1
(en)
*
|
2018-01-05 |
2019-07-11 |
Maxcyte, Inc. |
Chronic car treatment for cancer
|
WO2019136432A1
(en)
|
2018-01-08 |
2019-07-11 |
Novartis Ag |
Immune-enhancing rnas for combination with chimeric antigen receptor therapy
|
US11919937B2
(en)
|
2018-01-09 |
2024-03-05 |
Board Of Regents, The University Of Texas System |
T cell receptors for immunotherapy
|
EP3544618A4
(en)
*
|
2018-01-11 |
2020-02-12 |
Innovative Cellular Therapeutics Inc. |
MODIFIED CELL EXPANSION AND USES THEREOF
|
US10561686B2
(en)
|
2018-01-12 |
2020-02-18 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expansion and uses thereof
|
EP3737675A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND THEIR USES
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
CA3087481A1
(en)
|
2018-01-15 |
2019-07-18 |
Pfizer Inc. |
Methods of administering chimeric antigen receptor immunotherapy in combination with 4-1bb agonist
|
JP2021512147A
(ja)
|
2018-01-22 |
2021-05-13 |
エンドサイト・インコーポレイテッドEndocyte, Inc. |
Car t細胞の使用方法
|
KR20200116481A
(ko)
|
2018-01-29 |
2020-10-12 |
메르크 파텐트 게엠베하 |
Gcn2 억제제 및 이의 용도
|
CN111867581B
(zh)
|
2018-01-29 |
2023-12-26 |
默克专利股份有限公司 |
Gcn2抑制剂及其用途
|
KR102115236B1
(ko)
*
|
2018-01-29 |
2020-05-27 |
(주)에스엠티바이오 |
췌장 또는 담관계암 치료를 위한 키메라 항원 수용체
|
US11535903B2
(en)
|
2018-01-31 |
2022-12-27 |
Juno Therapeutics, Inc. |
Methods and reagents for assessing the presence or absence of replication competent virus
|
EP3746116A1
(en)
|
2018-01-31 |
2020-12-09 |
Novartis AG |
Combination therapy using a chimeric antigen receptor
|
KR20200128014A
(ko)
|
2018-01-31 |
2020-11-11 |
셀진 코포레이션 |
입양 세포 요법 및 체크포인트 억제제를 이용한 병용 요법
|
WO2019152957A1
(en)
|
2018-02-02 |
2019-08-08 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Dna-chimeric antigen receptor t cells for immunotherapy
|
US20210087511A1
(en)
*
|
2018-02-09 |
2021-03-25 |
Global Life Sciences Solutions Usa Llc |
Bioprocessing methods for cell therapy
|
EP3757133A4
(en)
*
|
2018-02-11 |
2021-12-01 |
Jiangsu Hengrui Medicine Co., Ltd. |
ISOLATED CHIMERIC ANTIGEN RECEPTOR, THIS MODIFIED T-CELL CONTAINED AND USES
|
WO2019157516A1
(en)
|
2018-02-12 |
2019-08-15 |
resTORbio, Inc. |
Combination therapies
|
CN110157677A
(zh)
*
|
2018-02-12 |
2019-08-23 |
深圳宾德生物技术有限公司 |
一种靶向性t淋巴细胞及其制备方法和应用
|
EP3752203A1
(en)
|
2018-02-13 |
2020-12-23 |
Novartis AG |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
WO2019160882A1
(en)
|
2018-02-13 |
2019-08-22 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
US20200377609A1
(en)
|
2018-02-14 |
2020-12-03 |
Kite Pharma, Inc. |
Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule
|
SG11202007513PA
(en)
|
2018-02-16 |
2020-09-29 |
Kite Pharma Inc |
Modified pluripotent stem cells and methods of making and use
|
AU2019222560A1
(en)
|
2018-02-17 |
2020-08-27 |
Flagship Pioneering Innovations V, Inc. |
Compositions and methods for membrane protein delivery
|
CA3093078A1
(en)
|
2018-03-06 |
2019-09-12 |
The Trustees Of The University Of Pennsylvania |
Prostate-specific membrane antigen cars and methods of use thereof
|
EP3762012A1
(en)
|
2018-03-09 |
2021-01-13 |
Ospedale San Raffaele S.r.l. |
Il-1 antagonist and toxicity induced by cell therapy
|
WO2019175328A1
(en)
|
2018-03-14 |
2019-09-19 |
Imba - Institut Für Molekulare Biotechnologie Gmbh |
Bh4pathwayactivationandusethereoffortreatingcancer
|
EP3765094A4
(en)
|
2018-03-15 |
2021-12-22 |
KSQ Therapeutics, Inc. |
GENE REGULATION COMPOSITIONS AND METHODS FOR IMPROVING IMMUNOTHERAPY
|
CN112040986A
(zh)
|
2018-03-15 |
2020-12-04 |
Ksq治疗公司 |
用于改进的免疫疗法的基因调控组合物和方法
|
DE102018108612A1
(de)
|
2018-03-21 |
2019-09-26 |
Immatics US, Inc. |
Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
|
US10760075B2
(en)
|
2018-04-30 |
2020-09-01 |
Snipr Biome Aps |
Treating and preventing microbial infections
|
CA3095027A1
(en)
|
2018-04-05 |
2019-10-10 |
Juno Therapeutics, Inc. |
T cell receptors and engineered cells expressing same
|
CN112585276A
(zh)
|
2018-04-05 |
2021-03-30 |
朱诺治疗学股份有限公司 |
产生表达重组受体的细胞的方法和相关组合物
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
2,2,─環二核苷酸
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
UY38182A
(es)
|
2018-04-10 |
2019-10-31 |
Amgen Inc |
Receptores quiméricos de dll3 y métodos para su uso
|
IL310416A
(en)
|
2018-04-12 |
2024-03-01 |
Kite Pharma Inc |
Chimeric T cell receptor therapy using tumor microenvironmental characteristics
|
US20210079384A1
(en)
|
2018-04-13 |
2021-03-18 |
The Johns Hopkins University |
Non-invasive detection of response to a targeted therapy
|
US20210155986A1
(en)
|
2018-04-13 |
2021-05-27 |
The Johns Hopkins University |
Non-invasive detection of response to immunotherapy
|
AU2019250692A1
(en)
|
2018-04-13 |
2020-11-05 |
Sangamo Therapeutics France |
Chimeric antigen receptor specific for Interleukin-23 receptor
|
EP3781162A1
(en)
|
2018-04-16 |
2021-02-24 |
Arrys Therapeutics, Inc. |
Ep4 inhibitors and use thereof
|
AU2019257340A1
(en)
|
2018-04-16 |
2020-10-15 |
Board Of Regents, The University Of Texas System |
Human kynureninase enzymes and uses thereof
|
US10869888B2
(en)
*
|
2018-04-17 |
2020-12-22 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expansion and uses thereof
|
WO2019203600A1
(ko)
|
2018-04-18 |
2019-10-24 |
앱클론(주) |
스위치 분자 및 스위처블 키메라 항원 수용체
|
US20210161958A1
(en)
*
|
2018-04-19 |
2021-06-03 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating melanoma with a chimeric antigen receptor
|
US10899735B2
(en)
|
2018-04-19 |
2021-01-26 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
TWI813673B
(zh)
|
2018-04-24 |
2023-09-01 |
德商馬克專利公司 |
抗增生化合物及其用途
|
JP7479293B2
(ja)
|
2018-04-24 |
2024-05-08 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
プテリジノン化合物およびその使用
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
US20210396739A1
(en)
|
2018-05-01 |
2021-12-23 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
CA3098865A1
(en)
*
|
2018-05-02 |
2019-11-07 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of phospholipase a2 receptor chimeric autoantibody receptor t cells
|
US20190359645A1
(en)
|
2018-05-03 |
2019-11-28 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
|
CN108753774B
(zh)
*
|
2018-05-03 |
2021-03-30 |
山东省齐鲁细胞治疗工程技术有限公司 |
干扰il-6表达的cd19-car-t细胞及其应用
|
MX2020011527A
(es)
|
2018-05-03 |
2021-02-26 |
Juno Therapeutics Inc |
Terapia de combinación de una terapia de células t-receptor de antígeno quimérico (car) y un inhibidor de cinasa.
|
CN112424342A
(zh)
|
2018-05-08 |
2021-02-26 |
生命科技公司 |
用于培养和扩增细胞的组合物和方法
|
KR20210008502A
(ko)
|
2018-05-11 |
2021-01-22 |
크리스퍼 테라퓨틱스 아게 |
암을 치료하기 위한 방법 및 조성물
|
CA3099152C
(en)
|
2018-05-14 |
2023-10-24 |
Gilead Sciences, Inc. |
Mcl-1 inhibitors
|
KR20210045953A
(ko)
|
2018-05-18 |
2021-04-27 |
더 존스 홉킨스 유니버시티 |
암의 평가 및/또는 치료를 위한 무 세포 dna
|
WO2019227003A1
(en)
|
2018-05-25 |
2019-11-28 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
CN108715859B
(zh)
*
|
2018-05-31 |
2021-08-03 |
中国医学科学院血液病医院(中国医学科学院血液学研究所) |
靶向cd22的嵌合抗原受体及其应用
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
TW202003021A
(zh)
|
2018-06-01 |
2020-01-16 |
美商凱特製藥公司 |
嵌合抗原受體t細胞療法
|
US20210371932A1
(en)
|
2018-06-01 |
2021-12-02 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
JP7411578B2
(ja)
*
|
2018-06-01 |
2024-01-11 |
マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ |
癌を治療するための物質及び方法
|
KR20210016390A
(ko)
|
2018-06-01 |
2021-02-15 |
노파르티스 아게 |
Bcma에 대한 결합 분자 및 이의 용도
|
EP3802825A1
(en)
|
2018-06-08 |
2021-04-14 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
EP3806888B1
(en)
|
2018-06-12 |
2024-01-31 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
TW202016139A
(zh)
|
2018-06-13 |
2020-05-01 |
瑞士商諾華公司 |
Bcma 嵌合抗原受體及其用途
|
KR20190141511A
(ko)
*
|
2018-06-14 |
2019-12-24 |
주식회사 녹십자랩셀 |
신규 펩티드, 이를 포함하는 키메라 항원 수용체 및 이를 발현하는 면역 세포
|
US20210363219A1
(en)
|
2018-06-15 |
2021-11-25 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
CA3104288A1
(en)
|
2018-06-21 |
2019-12-26 |
B-Mogen Biotechnologies, Inc. |
Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
EP3810780A1
(en)
|
2018-06-22 |
2021-04-28 |
Kite Pharma Eu B.V. |
Compositions and methods for making engineered t cells
|
EP3817763A4
(en)
|
2018-07-03 |
2022-04-13 |
SOTIO Biotech Inc. |
CHIMERA RECEPTORS COMBINED WITH TRANSMETABOLISM MOLECULES TO ENHANCE GLUCOSE IMPORT AND THERAPEUTIC USES THEREOF
|
EP3817748A4
(en)
|
2018-07-06 |
2022-08-24 |
Kymera Therapeutics, Inc. |
TRICYCLIC CRBN LIGANDS AND USES THEREOF
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
JP7105359B2
(ja)
|
2018-07-13 |
2022-07-22 |
ギリアード サイエンシーズ, インコーポレイテッド |
Pd-1/pd-l1阻害剤
|
WO2020017479A1
(ja)
|
2018-07-17 |
2020-01-23 |
ノイルイミューン・バイオテック株式会社 |
抗gpc3一本鎖抗体を含むcar
|
AU2019307607A1
(en)
|
2018-07-18 |
2021-02-11 |
Amgen Inc. |
Chimeric receptors to STEAP1 and methods of use thereof
|
CA3106612A1
(en)
|
2018-07-19 |
2020-01-23 |
Regeneron Pharmaceuticals, Inc. |
Chimeric antigen receptors with bcma specificity and uses thereof
|
CA3107383A1
(en)
|
2018-07-23 |
2020-01-30 |
Magenta Therapeutics, Inc. |
Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
|
CN108949759B
(zh)
*
|
2018-07-23 |
2021-06-01 |
合肥一兮生物科技有限公司 |
敲减人IL-15的siRNA、CD19 CAR表达载体、CAR-T细胞及构建方法和应用
|
KR20210038922A
(ko)
|
2018-08-02 |
2021-04-08 |
카이트 파마 인코포레이티드 |
키메라 항원 수용체 요법 t 세포 확장 동역학 및 그의 용도
|
EP3833742A2
(en)
|
2018-08-09 |
2021-06-16 |
Juno Therapeutics, Inc. |
Processes for generating engineered cells and compositions thereof
|
CA3108698A1
(en)
|
2018-08-09 |
2020-02-13 |
Juno Therapeutics, Inc. |
Methods for assessing integrated nucleic acids
|
EP3835320A4
(en)
|
2018-08-10 |
2022-06-01 |
Eutilex Co., Ltd. |
BINDING OF CHEMERA ANTIGEN RECEPTOR TO HLA-DR, AND CAR-T CELL
|
US20210177832A1
(en)
|
2018-08-20 |
2021-06-17 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease target binding and uses thereof
|
WO2020041387A1
(en)
|
2018-08-20 |
2020-02-27 |
The Brigham And Women's Hospital, Inc. |
Degradation domain modifications for spatio-temporal control of rna-guided nucleases
|
US20210355522A1
(en)
|
2018-08-20 |
2021-11-18 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease activity and uses thereof
|
CN110856724B
(zh)
*
|
2018-08-24 |
2022-05-27 |
杭州康万达医药科技有限公司 |
包含核酸及car修饰的免疫细胞的治疗剂及其应用
|
AU2019329984A1
(en)
|
2018-08-28 |
2021-03-11 |
Fred Hutchinson Cancer Center |
Methods and compositions for adoptive T cell therapy incorporating induced notch signaling
|
EP3844187A1
(en)
|
2018-08-28 |
2021-07-07 |
Vor Biopharma, Inc. |
Genetically engineered hematopoietic stem cells and uses thereof
|
CA3110096A1
(en)
|
2018-08-30 |
2020-03-05 |
Innovative Cellular Therapeutics CO., LTD. |
Chimeric antigen receptor cells for treating solid tumor
|
US20220348682A1
(en)
|
2018-08-30 |
2022-11-03 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Chimeric antigen receptor cells for treating solid tumor
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
US20210171909A1
(en)
|
2018-08-31 |
2021-06-10 |
Novartis Ag |
Methods of making chimeric antigen receptor?expressing cells
|
MX2021002393A
(es)
|
2018-08-31 |
2021-07-15 |
Novartis Ag |
Metodos de preparacion de celulas que expresan receptores de antigenos quimericos.
|
US11866494B2
(en)
*
|
2018-08-31 |
2024-01-09 |
Innovative Cellular Therapeutics Holdings, Ltd. |
CAR T therapy through uses of co-stimulation
|
JP2022500499A
(ja)
|
2018-09-07 |
2022-01-04 |
ピク セラピューティクス, インコーポレイテッド |
Eif4e阻害剤およびその使用
|
CA3111789A1
(en)
|
2018-09-11 |
2020-03-19 |
Juno Therapeutics, Inc. |
Methods for mass spectrometry analysis of engineered cell compositions
|
SG11202102644XA
(en)
|
2018-09-19 |
2021-04-29 |
Alpine Immune Sciences Inc |
Methods and uses of variant cd80 fusion proteins and related constructs
|
US11584799B2
(en)
|
2018-09-24 |
2023-02-21 |
Medical College Of Wisconsin, Inc. |
Anti-CD30 antibodies and methods for treating CD30+ cancer
|
WO2020068261A1
(en)
|
2018-09-28 |
2020-04-02 |
Massachusetts Institute Of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
US20220047633A1
(en)
|
2018-09-28 |
2022-02-17 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
US20210347851A1
(en)
*
|
2018-09-28 |
2021-11-11 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
SG11202103235PA
(en)
|
2018-10-01 |
2021-04-29 |
Adicet Bio Inc |
COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON- ENGINEERED γδ-Τ CELLS FOR TREATMENT OF HEMATOLOGICAL TUMORS
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
EP3488851A1
(en)
|
2018-10-03 |
2019-05-29 |
AVM Biotechnology, LLC |
Immunoablative therapies
|
US11179397B2
(en)
|
2018-10-03 |
2021-11-23 |
Gilead Sciences, Inc. |
Imidazopyrimidine derivatives
|
US11851663B2
(en)
|
2018-10-14 |
2023-12-26 |
Snipr Biome Aps |
Single-vector type I vectors
|
US20210379057A1
(en)
|
2018-10-16 |
2021-12-09 |
Massachusetts Institute Of Technology |
Nutlin-3a for use in treating a mycobacterium tuberculosis infection
|
AU2018447127A1
(en)
|
2018-10-22 |
2021-05-27 |
Shanghai GenBase Biotechnology Co., Ltd. |
Anti-CLDN128.2 antibody and uses thereof
|
EA202191107A1
(ru)
|
2018-10-23 |
2021-09-17 |
Ридженерон Фармасьютикалз, Инк. |
T-клеточные рецепторы ny-eso-1 и способы их применения
|
US20210386788A1
(en)
|
2018-10-24 |
2021-12-16 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
US11236085B2
(en)
|
2018-10-24 |
2022-02-01 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
WO2020086989A1
(en)
*
|
2018-10-25 |
2020-04-30 |
Innovative Cellular Therapeutics CO., LTD. |
Increase or maintaining t-cell subpopulations in adoptive t-cell therapy
|
US20220170097A1
(en)
|
2018-10-29 |
2022-06-02 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
WO2020092057A1
(en)
|
2018-10-30 |
2020-05-07 |
Yale University |
Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
|
BR112021008133A2
(pt)
|
2018-10-31 |
2021-10-05 |
Juno Therapeutics Gmbh |
Métodos para seleção e estimulação de células e aparelhos para os mesmos
|
JP7273172B2
(ja)
|
2018-10-31 |
2023-05-12 |
ギリアード サイエンシーズ, インコーポレイテッド |
Hpk1阻害活性を有する置換6-アザベンゾイミダゾール化合物
|
MX2021005047A
(es)
|
2018-10-31 |
2021-09-08 |
Gilead Sciences Inc |
Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1.
|
MX2021005024A
(es)
|
2018-11-01 |
2021-07-21 |
Juno Therapeutics Inc |
Metodos de tratamiento que utilizan receptores de antigenos quimericos especificos para antigeno de maduracion de celulas b.
|
BR112021008738A2
(pt)
|
2018-11-06 |
2021-11-03 |
Juno Therapeutics Inc |
Processo para produzir células t geneticamente construídas
|
CN109467604A
(zh)
*
|
2018-11-07 |
2019-03-15 |
南京卡提医学科技有限公司 |
嵌合抗原受体DAP12-T2A-CD8α-CD19scFv-TREM1及其用途
|
CN109503717A
(zh)
*
|
2018-11-07 |
2019-03-22 |
南京卡提医学科技有限公司 |
嵌合抗原受体DAP12-T2A-CD8α-CD19scfv-NKp44及其用途
|
WO2020097346A1
(en)
*
|
2018-11-07 |
2020-05-14 |
Unum Therapeutics Inc. |
ANTI-GPC3 CHIMERIC ANTIGEN RECEPTORS (CARs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF
|
SG11202104411VA
(en)
|
2018-11-08 |
2021-05-28 |
Juno Therapeutics Inc |
Methods and combinations for treatment and t cell modulation
|
US20230043255A1
(en)
|
2018-11-14 |
2023-02-09 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions for t cell delivery
|
EP3880238A1
(en)
|
2018-11-16 |
2021-09-22 |
Juno Therapeutics, Inc. |
Methods of dosing engineered t cells for the treatment of b cell malignancies
|
EP3883955A1
(en)
|
2018-11-19 |
2021-09-29 |
Board of Regents, The University of Texas System |
A modular, polycistronic vector for car and tcr transduction
|
US10918667B2
(en)
|
2018-11-20 |
2021-02-16 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expressing therapeutic agent and uses thereof
|
EA202191463A1
(ru)
|
2018-11-28 |
2021-10-13 |
Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем |
Мультиплексное редактирование генома иммунных клеток для повышения функциональности и устойчивости к подавляющей среде
|
AU2019386830A1
(en)
|
2018-11-29 |
2021-06-24 |
Board Of Regents, The University Of Texas System |
Methods for ex vivo expansion of natural killer cells and use thereof
|
JP2022513689A
(ja)
|
2018-11-30 |
2022-02-09 |
ジュノー セラピューティクス インコーポレイテッド |
養子細胞療法におけるb細胞悪性腫瘍の投与および処置のための方法
|
KR20210117260A
(ko)
|
2018-11-30 |
2021-09-28 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 요법을 사용한 치료방법
|
CN113423427A
(zh)
|
2018-11-30 |
2021-09-21 |
凯麦拉医疗公司 |
Irak降解剂和其用途
|
CN113260633A
(zh)
|
2018-12-05 |
2021-08-13 |
豪夫迈·罗氏有限公司 |
用于癌症免疫疗法的诊断方法和组合物
|
SG11202106053SA
(en)
*
|
2018-12-07 |
2021-07-29 |
Gracell Biotechnologies Shanghai Co Ltd |
Compositions and methods for immunotherapy
|
KR20210101270A
(ko)
|
2018-12-10 |
2021-08-18 |
암젠 인크 |
돌연변이 피기백 트랜스포사제
|
WO2020123716A1
(en)
|
2018-12-11 |
2020-06-18 |
Obsidian Therapeutics, Inc. |
Membrane bound il12 compositions and methods for tunable regulation
|
WO2020123691A2
(en)
|
2018-12-12 |
2020-06-18 |
Kite Pharma, Inc |
Chimeric antigen and t cell receptors and methods of use
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
EP3670530A1
(en)
|
2018-12-18 |
2020-06-24 |
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
KR20210106437A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
|
CN113474840A
(zh)
|
2018-12-21 |
2021-10-01 |
百欧恩泰美国公司 |
用于预测hla ii类特异性表位及表征cd4+ t细胞的方法和***
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
CN113382741A
(zh)
*
|
2019-01-06 |
2021-09-10 |
艾宾妥斯生物公司 |
Car t细胞方法和构建体
|
PE20212198A1
(es)
|
2019-01-29 |
2021-11-16 |
Juno Therapeutics Inc |
Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1)
|
MX2021009763A
(es)
|
2019-02-15 |
2021-09-08 |
Novartis Ag |
Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos.
|
KR20210118945A
(ko)
|
2019-02-15 |
2021-10-01 |
유니버시티 오브 써던 캘리포니아 |
Lym-1 및 lym-2 항체 조성물 및 개선된 car 구성물
|
CA3123519A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
MX2021010150A
(es)
|
2019-02-25 |
2021-09-14 |
Novartis Ag |
Composiciones de particulas de silice mesoporosa para administracion viral.
|
WO2020180591A1
(en)
|
2019-03-01 |
2020-09-10 |
Allogene Therapeutics, Inc. |
Dll3 targeting chimeric antigen receptors and binding agents
|
JP2022522473A
(ja)
*
|
2019-03-01 |
2022-04-19 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
液性腫瘍からの腫瘍浸潤リンパ球の拡大培養及びその治療的使用
|
AU2020232691B2
(en)
|
2019-03-05 |
2023-06-29 |
Nkarta, Inc. |
CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
|
EP3935066A1
(en)
|
2019-03-07 |
2022-01-12 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
KR20210137517A
(ko)
|
2019-03-07 |
2021-11-17 |
인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. |
2'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
|
US11766447B2
(en)
|
2019-03-07 |
2023-09-26 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
CA3128971A1
(en)
|
2019-03-08 |
2020-09-17 |
Klinikum Der Universitat Munchen |
Ccr8 expressing lymphocytes for targeted tumor therapy
|
CA3132840A1
(en)
|
2019-03-08 |
2020-09-17 |
Obsidian Therapeutics, Inc. |
Human carbonic anhydrase 2 compositions and methods for tunable regulation
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
WO2020191079A1
(en)
|
2019-03-18 |
2020-09-24 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
CA3133155A1
(en)
|
2019-03-19 |
2020-09-24 |
Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron |
Combination therapy for the treatment for cancer
|
US20230074800A1
(en)
|
2019-03-21 |
2023-03-09 |
Novartis Ag |
Car-t cell therapies with enhanced efficacy
|
SG11202110828UA
(en)
|
2019-04-02 |
2021-10-28 |
Bicycletx Ltd |
Bicycle toxin conjugates and uses thereof
|
US11485750B1
(en)
|
2019-04-05 |
2022-11-01 |
Kymera Therapeutics, Inc. |
STAT degraders and uses thereof
|
EP3953455A1
(en)
|
2019-04-12 |
2022-02-16 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
TWI751517B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
EP3959320A1
(en)
|
2019-04-24 |
2022-03-02 |
Novartis AG |
Compositions and methods for selective protein degradation
|
JP2022532996A
(ja)
|
2019-04-26 |
2022-07-21 |
アロジーン セラピューティクス,インコーポレイテッド |
リツキシマブ耐性キメラ抗原受容体およびその用途
|
CA3132509A1
(en)
|
2019-04-26 |
2020-10-29 |
Allogene Therapeutics, Inc. |
Methods of manufacturing allogeneic car t cells
|
CA3133333A1
(en)
|
2019-04-30 |
2020-04-30 |
Brian Scott GARRISON |
Chimeric receptors and methods of use thereof
|
AU2020267057A1
(en)
|
2019-04-30 |
2021-11-18 |
Crispr Therapeutics Ag |
Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19
|
MX2021013219A
(es)
|
2019-05-01 |
2022-02-17 |
Juno Therapeutics Inc |
Celulas que expresan un receptor recombinante de un locus de tgfbr2 modificado, polinucleotidos relacionados y metodos.
|
BR112021021200A2
(pt)
|
2019-05-01 |
2021-12-21 |
Juno Therapeutics Inc |
Células expressando um receptor quimérico de um locus cd247 modificado, polinucleotídeos relacionados e métodos
|
TW202108150A
(zh)
|
2019-05-03 |
2021-03-01 |
美商凱特製藥公司 |
投與嵌合抗原受體免疫療法之方法
|
CA3139346A1
(en)
|
2019-05-07 |
2020-11-12 |
Gracell Biotechnologies (Shanghai) Co., Ltd. |
Engineered immune cell targeting bcma and use thereof
|
WO2020236967A1
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Random crispr-cas deletion mutant
|
AU2020279371A1
(en)
|
2019-05-22 |
2021-12-23 |
Leidos, Inc. |
LAG 3 binding peptides
|
US20220251538A1
(en)
|
2019-05-23 |
2022-08-11 |
Matjaz Vogelsang |
Method for removal of nucleic acids impurities from liquid composition comprising genetically engineered particles or proteins
|
US11453681B2
(en)
|
2019-05-23 |
2022-09-27 |
Gilead Sciences, Inc. |
Substituted eneoxindoles and uses thereof
|
WO2020243371A1
(en)
|
2019-05-28 |
2020-12-03 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
WO2020243423A1
(en)
|
2019-05-31 |
2020-12-03 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2020246563A1
(ja)
*
|
2019-06-05 |
2020-12-10 |
中外製薬株式会社 |
抗体切断部位結合分子
|
BR112021024404A2
(pt)
|
2019-06-07 |
2022-04-19 |
Juno Therapeutics Inc |
Cultura de célula t automatizada
|
MX2021015097A
(es)
|
2019-06-12 |
2022-04-01 |
Obsidian Therapeutics Inc |
Composiciones de ca2 y metodos para regulación ajustable.
|
EP3983537A1
(en)
|
2019-06-12 |
2022-04-20 |
Obsidian Therapeutics, Inc. |
Ca2 compositions and methods for tunable regulation
|
MX2021015317A
(es)
|
2019-06-12 |
2022-03-11 |
Juno Therapeutics Inc |
Terapia de combinacion de una terapia citotoxica mediada por celulas y un inhibidor de una proteina de la familia bcl2 de prosupervivencia.
|
WO2020257823A2
(en)
|
2019-06-21 |
2020-12-24 |
Kite Pharma, Inc. |
TGF-β RECEPTORS AND METHODS OF USE
|
JP2022539032A
(ja)
|
2019-06-24 |
2022-09-07 |
チルドレンズ ホスピタル ロサンゼルス |
ヒト胸腺細胞形成およびt細胞機能を強化するためのbcl11b過剰発現
|
EP3990476A1
(en)
|
2019-06-25 |
2022-05-04 |
Gilead Sciences, Inc. |
Flt3l-fc fusion proteins and methods of use
|
US11642409B2
(en)
|
2019-06-26 |
2023-05-09 |
Massachusetts Insttute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
JP2022539248A
(ja)
|
2019-07-02 |
2022-09-07 |
フレッド ハッチンソン キャンサー リサーチ センター |
組換えad35ベクター及び関連遺伝子治療改善
|
EP3994173A1
(en)
|
2019-07-02 |
2022-05-11 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Monoclonal antibodies that bind egfrviii and their use
|
GB201909573D0
(en)
|
2019-07-03 |
2019-08-14 |
Cancer Research Tech Ltd |
Modulation of T cell cytotoxicity and related therapy
|
JPWO2021010326A1
(hu)
|
2019-07-12 |
2021-01-21 |
|
|
WO2021011907A1
(en)
|
2019-07-18 |
2021-01-21 |
Gpb Scientific, Inc. |
Ordered processing of blood products to produce therapeutically active cells
|
JP2022542102A
(ja)
|
2019-07-23 |
2022-09-29 |
ムネモ・セラピューティクス |
Suv39h1欠損免疫細胞
|
CA3147903A1
(en)
|
2019-07-24 |
2021-01-28 |
Regeneron Pharmaceuticals, Inc. |
Chimeric antigen receptors with mage-a4 specificity and uses thereof
|
CN110305849B
(zh)
*
|
2019-08-01 |
2021-03-30 |
广东万海细胞生物科技有限公司 |
稳定表达car的t细胞及其制备方法与应用
|
GB201911066D0
(en)
|
2019-08-02 |
2019-09-18 |
Achilles Therapeutics Ltd |
T cell therapy
|
KR20220053587A
(ko)
*
|
2019-08-09 |
2022-04-29 |
에이투 바이오쎄라퓨틱스, 인크. |
이형접합성 소실에 반응성인 세포 표면 수용체
|
WO2021030627A1
(en)
|
2019-08-13 |
2021-02-18 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
EP4017527A1
(en)
|
2019-08-22 |
2022-06-29 |
Juno Therapeutics, Inc. |
Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
|
US20230092895A1
(en)
|
2019-08-30 |
2023-03-23 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
KR20220073738A
(ko)
|
2019-08-30 |
2022-06-03 |
주노 쎄러퓨티크스 인코퍼레이티드 |
세포 분류를 위한 기계 학습 방법
|
US20220298501A1
(en)
|
2019-08-30 |
2022-09-22 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
AU2020343407A1
(en)
|
2019-09-02 |
2022-03-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Immunotherapy targeting tumor neoantigenic peptides
|
AU2020341454A1
(en)
|
2019-09-03 |
2022-03-10 |
Sana Biotechnology, Inc. |
CD24-associated particles and related methods and uses thereof
|
US20210062150A1
(en)
|
2019-09-03 |
2021-03-04 |
Allogene Therapeutics, Inc. |
Methods of preparing t cells for t cell therapy
|
WO2021046451A1
(en)
|
2019-09-06 |
2021-03-11 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
EP4028523A1
(en)
|
2019-09-09 |
2022-07-20 |
Scribe Therapeutics Inc. |
Compositions and methods for use in immunotherapy
|
US11058725B2
(en)
|
2019-09-10 |
2021-07-13 |
Obsidian Therapeutics, Inc. |
CA2 compositions and methods for tunable regulation
|
US20220347216A1
(en)
*
|
2019-09-13 |
2022-11-03 |
Ohio State Innovation Foundation |
Nk cell immunotherapy compositions, methods of making and methods of using same
|
JP2022547719A
(ja)
|
2019-09-13 |
2022-11-15 |
ニンバス サターン, インコーポレイテッド |
Hpk1アンタゴニストおよびその使用
|
WO2021053559A1
(en)
|
2019-09-18 |
2021-03-25 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
EP4031654A4
(en)
*
|
2019-09-20 |
2023-11-22 |
The University of North Carolina at Chapel Hill |
MODIFIED T CELLS AND METHOD FOR PRODUCING THEREOF
|
EP4032907A4
(en)
|
2019-09-20 |
2023-07-05 |
Shanghai Genbase Biotechnology Co., Ltd. |
BCMA-TARGETING CHEMERA ANTIGENIC ANTIBODIES AND RECEPTOR
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
KR102287180B1
(ko)
*
|
2019-10-01 |
2021-08-09 |
충북대학교 산학협력단 |
Cd138에 특이적으로 결합하는 키메릭 항원 수용체, 이를 발현하는 면역세포 및 이의 항암 용도
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
CN115103910A
(zh)
|
2019-10-03 |
2022-09-23 |
工匠开发实验室公司 |
具有工程化的双引导核酸的crispr***
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
US11795223B2
(en)
|
2019-10-18 |
2023-10-24 |
Forty Seven, Inc. |
Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
|
WO2021078910A1
(en)
|
2019-10-22 |
2021-04-29 |
Institut Curie |
Immunotherapy targeting tumor neoantigenic peptides
|
EP4048696A1
(en)
|
2019-10-23 |
2022-08-31 |
Kite Pharma, Inc. |
Anti-idiotypic antigen binding molecules and methods of use thereof
|
CN110679588A
(zh)
*
|
2019-10-23 |
2020-01-14 |
厦门生命互联科技有限公司 |
一种嵌合抗原受体t细胞冻存介质及用途
|
TWI717880B
(zh)
*
|
2019-10-24 |
2021-02-01 |
中國醫藥大學附設醫院 |
Hla-g特異性嵌合抗原受體、核酸、hla-g特異性嵌合抗原受體表達質體、表達hla-g特異性嵌合抗原受體細胞、其用途以及用於治療癌症之醫藥組合物
|
KR20220101641A
(ko)
|
2019-10-30 |
2022-07-19 |
주노 테라퓨틱스 게엠베하 |
세포 선택 및/또는 자극 장치 및 사용 방법
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
AU2020374947A1
(en)
|
2019-10-31 |
2022-03-31 |
Forty Seven, Inc. |
Anti-CD47 and anti-CD20 based treatment of blood cancer
|
US20220403002A1
(en)
|
2019-11-01 |
2022-12-22 |
Kyoto Prefectural Public University Corporation |
B-cell antibody receptor and use thereof
|
EP4054623A1
(en)
|
2019-11-07 |
2022-09-14 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and (s)-3-[4-(4-morpholin-4 ylmethyl-benzyloxy)-l-oxo-l,3-dihydro-isoindol-2-yl]- piperidine-2,6-dione
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
AU2020389422A1
(en)
|
2019-11-20 |
2022-06-02 |
Gi Cell, Inc. |
Medium composition for culturing T cells and method for culturing T cells using same
|
MX2022006308A
(es)
|
2019-11-26 |
2022-06-22 |
Ikena Oncology Inc |
Derivados de carbazol polimorfos y usos de los mismos.
|
TW202134285A
(zh)
|
2019-11-26 |
2021-09-16 |
瑞士商諾華公司 |
Cd19和cd22嵌合抗原受體及其用途
|
CA3163104A1
(en)
|
2019-11-26 |
2021-06-03 |
Novartis Ag |
Chimeric antigen receptors and uses thereof
|
WO2021113770A1
(en)
|
2019-12-06 |
2021-06-10 |
Juno Therapeutics, Inc. |
Methods related to toxicity and response associated with cell therapy for treating b cell malignancies
|
US20230192869A1
(en)
|
2019-12-06 |
2023-06-22 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
|
JP2023504740A
(ja)
|
2019-12-06 |
2023-02-06 |
ジュノー セラピューティクス インコーポレイテッド |
Bcma標的結合ドメインに対する抗イディオタイプ抗体ならびに関連する組成物および方法
|
WO2021127283A2
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
IL293917A
(en)
|
2019-12-17 |
2022-08-01 |
Kymera Therapeutics Inc |
Iraq joints and their uses
|
JP2023507190A
(ja)
|
2019-12-20 |
2023-02-21 |
ノバルティス アーゲー |
増殖性疾患を治療するための抗TGFβ抗体及びチェックポイント阻害薬の使用
|
CN115297931A
(zh)
|
2019-12-23 |
2022-11-04 |
凯麦拉医疗公司 |
Smarca降解剂和其用途
|
MX2022007930A
(es)
|
2019-12-24 |
2022-08-08 |
Carna Biosciences Inc |
Compuestos moduladores de diacilglicerol quinasa.
|
JP7088902B2
(ja)
*
|
2019-12-27 |
2022-06-21 |
クレージュ メディカル カンパニー,リミテッド |
キメラ抗原受容体タンパク質をコードする核酸およびキメラ抗原受容体タンパク質を発現するtリンパ球
|
EP4081344A1
(en)
|
2019-12-28 |
2022-11-02 |
GPB Scientific, Inc. |
Microfluidic cartridges for processing particles and cells
|
CN113150167A
(zh)
*
|
2020-01-22 |
2021-07-23 |
中国人民解放军总医院第五医学中心 |
一种能够反转pd-1免疫抑制信号的car t细胞结构em1设计
|
AU2021211713A1
(en)
|
2020-01-23 |
2022-08-25 |
The Children's Medical Center Corporation |
Stroma-free T cell differentiation from human pluripotent stem cells
|
IL294724A
(en)
|
2020-01-24 |
2022-09-01 |
Juno Therapeutics Inc |
Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in stress cell therapy
|
JP2023511417A
(ja)
|
2020-01-24 |
2023-03-17 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
黒色腫において優先的に発現する抗原(prame)t細胞受容体およびそれらの使用方法
|
KR20220146480A
(ko)
|
2020-01-28 |
2022-11-01 |
주노 쎄러퓨티크스 인코퍼레이티드 |
T 세포 형질도입 방법
|
WO2021155897A1
(en)
|
2020-02-03 |
2021-08-12 |
MVZ Prof. Niendorf Pathologie Hamburg-West GmbH |
Marker set for the diagnosis and treatment of cancer
|
EP4103203A1
(en)
|
2020-02-12 |
2022-12-21 |
Juno Therapeutics, Inc. |
Bcma-directed chimeric antigen receptor t cell compositions and methods and uses thereof
|
IL295384A
(en)
|
2020-02-12 |
2022-10-01 |
Juno Therapeutics Inc |
Preparations of t cells with a chimeric antigen receptor directed against cd19 and methods and uses thereof
|
PE20231067A1
(es)
|
2020-02-14 |
2023-07-17 |
Jounce Therapeutics Inc |
Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos
|
EP4107173A1
(en)
|
2020-02-17 |
2022-12-28 |
Board of Regents, The University of Texas System |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
EP4110376A2
(en)
|
2020-02-27 |
2023-01-04 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
MX2022010685A
(es)
|
2020-02-27 |
2022-09-23 |
Novartis Ag |
Metodos de produccion de celulas que expresan receptores de antigeno quimericos.
|
CN111269326A
(zh)
*
|
2020-02-28 |
2020-06-12 |
南京北恒生物科技有限公司 |
新型嵌合抗原受体及其用途
|
CA3170411A1
(en)
|
2020-03-03 |
2021-09-10 |
Christopher L. Vandeusen |
Eif4e inhibitors and uses thereof
|
AU2021357520A1
(en)
|
2020-03-05 |
2022-09-29 |
Neotx Therapeutics Ltd. |
Methods and compositions for treating cancer with immune cells
|
BR112022018105A2
(pt)
|
2020-03-10 |
2022-11-22 |
Massachusetts Inst Technology |
Métodos para gerar células nk tipo-memória modificadas e composições das mesmas
|
EP4118112A1
(en)
|
2020-03-10 |
2023-01-18 |
Massachusetts Institute of Technology |
Compositions and methods for immunotherapy of npm1c-positive cancer
|
CN113402612A
(zh)
|
2020-03-17 |
2021-09-17 |
西比曼生物科技(香港)有限公司 |
靶向cd19和cd20的联合嵌合抗原受体及其应用
|
CA3171258A1
(en)
|
2020-03-19 |
2021-09-23 |
Nan JI |
Mdm2 degraders and uses thereof
|
CA3178308A1
(en)
|
2020-03-31 |
2021-10-07 |
Sana Biotechnology, Inc. |
Targeted lipid particles and compositions and uses thereof
|
EP3892720A1
(en)
|
2020-04-06 |
2021-10-13 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Presenting cell and use thereof in cell therapy
|
WO2021207689A2
(en)
|
2020-04-10 |
2021-10-14 |
Juno Therapeutics, Inc. |
Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
|
US20230340040A1
(en)
*
|
2020-04-14 |
2023-10-26 |
St. Jude Children's Research Hospital, Inc. |
Chimeric myd88 receptors
|
US20210324331A1
(en)
*
|
2020-04-15 |
2021-10-21 |
Amgen Inc. |
Process for generating genetically engineered autologous t cells
|
GB202005599D0
(en)
|
2020-04-17 |
2020-06-03 |
Univ London |
Modulation of t cell cytotoxicity and related therapy
|
GB202006254D0
(en)
|
2020-04-28 |
2020-06-10 |
Institute Of Cancer Res |
Anti-cancer vaccines and related therapy
|
WO2021222330A2
(en)
|
2020-04-28 |
2021-11-04 |
Juno Therapeutics, Inc. |
Combination of bcma-directed t cell therapy and an immunomodulatory compound
|
IL297594A
(en)
|
2020-04-28 |
2022-12-01 |
Achilles Therapeutics Uk Ltd |
t cell therapy
|
US20210338833A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
MX2022013619A
(es)
|
2020-05-01 |
2022-11-16 |
Gilead Sciences Inc |
Compuestos de 2,4-dioxopirimidina que inhiben cd73.
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
CN115485303A
(zh)
|
2020-05-05 |
2022-12-16 |
瑞泽恩制药公司 |
包含CD28ζ和CD3ζ的CAR
|
WO2021228999A1
(en)
|
2020-05-12 |
2021-11-18 |
Institut Curie |
Neoantigenic epitopes associated with sf3b1 mutations
|
EP4150640A1
(en)
|
2020-05-13 |
2023-03-22 |
Juno Therapeutics, Inc. |
Methods of identifying features associated with clinical response and uses thereof
|
CN115835873A
(zh)
|
2020-05-13 |
2023-03-21 |
朱诺治疗学股份有限公司 |
用于产生表达重组受体的供体分批细胞的方法
|
WO2021231954A1
(en)
*
|
2020-05-15 |
2021-11-18 |
Precision Biosciences, Inc. |
Methods for immunotherapy
|
EP4153301A2
(en)
|
2020-05-21 |
2023-03-29 |
Board of Regents, The University of Texas System |
T cell receptors with vgll1 specificity and uses thereof
|
AU2021278356A1
(en)
|
2020-05-27 |
2022-11-03 |
Antion Biosciences Sa |
Adapter molecules to re-direct CAR T cells to an antigen of interest
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
EP4161536A1
(en)
|
2020-06-04 |
2023-04-12 |
Carisma Therapeutics Inc. |
Novel constructs for chimeric antigen receptors
|
WO2021244654A1
(en)
*
|
2020-06-05 |
2021-12-09 |
Nanjing Legend Biotech Co., Ltd. |
Activation induced cytokine production in immune cells
|
CA3186600A1
(en)
|
2020-06-08 |
2021-12-16 |
Janssen Biotech, Inc. |
Cell-based assay for determining the in vitro tumor killing activity of chimeric antigen expressing immune cells
|
CN116096862A
(zh)
|
2020-06-11 |
2023-05-09 |
诺华股份有限公司 |
Zbtb32抑制剂及其用途
|
WO2021260528A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
US20230293530A1
(en)
|
2020-06-24 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
CN116234558A
(zh)
|
2020-06-26 |
2023-06-06 |
朱诺治疗学有限公司 |
条件性地表达重组受体的工程化t细胞、相关多核苷酸和方法
|
JP2023535371A
(ja)
|
2020-07-17 |
2023-08-17 |
シミュレックス インコーポレイテッド |
免疫抑制シグナル伝達をリダイレクトするためのキメラMyD88受容体ならびに関連する組成物および方法
|
KR102297396B1
(ko)
|
2020-07-29 |
2021-09-06 |
(주)티카로스 |
면역시냅스를 안정화시키는 키메라 항원 수용체(car) t 세포
|
WO2022023576A1
(en)
|
2020-07-30 |
2022-02-03 |
Institut Curie |
Immune cells defective for socs1
|
WO2022026496A2
(en)
|
2020-07-31 |
2022-02-03 |
Leidos, Inc. |
Lag3 binding peptides
|
WO2022029573A1
(en)
|
2020-08-03 |
2022-02-10 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
US20230324408A1
(en)
|
2020-08-05 |
2023-10-12 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
|
AU2021325941A1
(en)
|
2020-08-13 |
2023-03-09 |
Sana Biotechnology, Inc. |
Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
|
AU2021325947A1
(en)
|
2020-08-13 |
2023-03-02 |
Yale University |
Compositions and methods for engineering and selection of CAR T cells with desired phenotypes
|
WO2022036041A1
(en)
|
2020-08-14 |
2022-02-17 |
Kite Pharma, Inc |
Improving immune cell function
|
AU2021327130A1
(en)
|
2020-08-17 |
2023-03-02 |
Bicycletx Limited |
Bicycle conjugates specific for Nectin-4 and uses thereof
|
JP2023538115A
(ja)
|
2020-08-20 |
2023-09-06 |
エー2 バイオセラピューティクス, インコーポレイテッド |
Ceacam陽性がんを治療するための組成物及び方法
|
KR20230051677A
(ko)
|
2020-08-20 |
2023-04-18 |
에이투 바이오쎄라퓨틱스, 인크. |
메소텔린 양성 암을 치료하기 위한 조성물 및 방법
|
JP2023538118A
(ja)
|
2020-08-21 |
2023-09-06 |
ノバルティス アーゲー |
Car発現細胞のインビボ生成のための組成物及び方法
|
EP4204545A2
(en)
|
2020-08-25 |
2023-07-05 |
Kite Pharma, Inc. |
T cells with improved functionality
|
WO2022046840A1
(en)
*
|
2020-08-26 |
2022-03-03 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Hybrid allosteric receptor-engineered stem cells
|
AU2021361844A1
(en)
|
2020-10-12 |
2023-06-15 |
Leidos, Inc. |
Immunomodulatory peptides
|
CN116600816A
(zh)
*
|
2020-10-16 |
2023-08-15 |
尼昂克技术公司 |
用于治疗cns感染的poh和瑞德西韦的组合
|
US20220155299A1
(en)
|
2020-10-28 |
2022-05-19 |
Kite Pharma, Inc. |
Flow cytometric method for characterization of t-cell impurities
|
CA3199839A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
WO2022104109A1
(en)
|
2020-11-13 |
2022-05-19 |
Catamaran Bio, Inc. |
Genetically modified natural killer cells and methods of use thereof
|
WO2022104061A1
(en)
|
2020-11-13 |
2022-05-19 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
CN112195250A
(zh)
*
|
2020-11-20 |
2021-01-08 |
山东省医学科学院附属医院 |
一种qPCR试剂盒及应用
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
WO2022133030A1
(en)
|
2020-12-16 |
2022-06-23 |
Juno Therapeutics, Inc. |
Combination therapy of a cell therapy and a bcl2 inhibitor
|
AU2021401052A1
(en)
|
2020-12-18 |
2023-06-22 |
Century Therapeutics, Inc. |
Chimeric antigen receptor systems with adaptable receptor specificity
|
US20220204930A1
(en)
|
2020-12-24 |
2022-06-30 |
Kite Pharma, Inc. |
Prostate cancer chimeric antigen receptors
|
CA3203531A1
(en)
|
2020-12-30 |
2022-07-07 |
Simon Olivares |
Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
|
KR20230137900A
(ko)
|
2020-12-31 |
2023-10-05 |
사나 바이오테크놀로지, 인크. |
Car-t 활성을 조정하기 위한 방법 및 조성물
|
JP2024502599A
(ja)
|
2021-01-10 |
2024-01-22 |
カイト ファーマ インコーポレイテッド |
T細胞療法
|
TW202242121A
(zh)
|
2021-01-11 |
2022-11-01 |
美商薩那生物科技公司 |
靶向cd8之病毒載體之用途
|
JP2024502189A
(ja)
|
2021-01-11 |
2024-01-17 |
バイシクルティーエクス・リミテッド |
癌を処置する方法
|
IL304031A
(en)
|
2021-01-14 |
2023-08-01 |
Inst Curie |
Variants of single-domain HER2 antibodies and their chimeric antigenic receptors
|
UY39610A
(es)
|
2021-01-20 |
2022-08-31 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
CN117062611A
(zh)
|
2021-01-26 |
2023-11-14 |
惠和生物技术(上海)有限公司 |
嵌合抗原受体(car)构建体和表达car构建体的nk细胞
|
WO2022165461A1
(en)
*
|
2021-01-27 |
2022-08-04 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Bi-specific car t cells for b cell malignancies
|
JP2024508223A
(ja)
|
2021-01-28 |
2024-02-26 |
アロジーン セラピューティクス,インコーポレイテッド |
免疫細胞を形質導入する方法
|
JP2024506831A
(ja)
|
2021-01-28 |
2024-02-15 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
サイトカイン放出症候群を治療するための組成物及び方法
|
JP2024506858A
(ja)
|
2021-02-02 |
2024-02-15 |
リミナル・バイオサイエンシーズ・リミテッド |
Gpr84アンタゴニストおよびその使用
|
IL304905A
(en)
|
2021-02-15 |
2023-10-01 |
Kymera Therapeutics Inc |
IRAK4 joints and their uses
|
JP2024507199A
(ja)
|
2021-02-20 |
2024-02-16 |
カイト ファーマ インコーポレイテッド |
免疫療法を選択するための遺伝子マーカー
|
US20240108654A1
(en)
|
2021-03-03 |
2024-04-04 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and a dgk inhibitor
|
US11926625B2
(en)
|
2021-03-05 |
2024-03-12 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
JP2024512337A
(ja)
|
2021-03-05 |
2024-03-19 |
シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド |
抗cldn6抗体およびその使用
|
EP4304635A1
(en)
|
2021-03-11 |
2024-01-17 |
Mnemo Therapeutics |
Tumor neoantigenic peptides and uses thereof
|
AU2022232196A1
(en)
|
2021-03-11 |
2023-09-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Transmembrane neoantigenic peptides
|
JP2024510162A
(ja)
|
2021-03-11 |
2024-03-06 |
カイト ファーマ インコーポレイテッド |
免疫細胞機能の改善
|
EP4304632A2
(en)
|
2021-03-11 |
2024-01-17 |
Mnemo Therapeutics |
Tumor neoantigenic peptides
|
TW202300522A
(zh)
|
2021-03-17 |
2023-01-01 |
日商第一三共股份有限公司 |
編碼對抗乙醯膽鹼受體自體抗體之嵌合受體之基因
|
JP2024511420A
(ja)
|
2021-03-22 |
2024-03-13 |
ジュノー セラピューティクス インコーポレイテッド |
ウイルスベクター粒子の効力を評価する方法
|
US20240168012A1
(en)
|
2021-03-22 |
2024-05-23 |
Juno Therapeutics, Inc. |
Methods of determining potency of a therapeutic cell composition
|
MX2023011370A
(es)
|
2021-03-29 |
2023-11-24 |
Juno Therapeutics Inc |
Combinacion de una terapia con celulas t con receptores de antigenos quimericos (car) y un compuesto inmunomodulador para el tratamiento de linfoma.
|
AU2022246593A1
(en)
|
2021-03-29 |
2023-10-12 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
GB202109886D0
(en)
|
2021-07-08 |
2021-08-25 |
Achilles Therapeutics Uk Ltd |
Assay
|
EP4320435A1
(en)
|
2021-04-09 |
2024-02-14 |
Achilles Therapeutics UK Limited |
Batch release assay for pharmaceutical products relating to t cell therapies
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症
|
EP4322959A2
(en)
|
2021-04-16 |
2024-02-21 |
Celgene Corporation |
Combination therapies with bcma-directed t cell therapy
|
EP4323066A1
(en)
|
2021-04-16 |
2024-02-21 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2022221028A1
(en)
|
2021-04-16 |
2022-10-20 |
Kite Pharma, Inc. |
Taci/bcma dual binding molecules
|
EP4322991A1
(en)
|
2021-04-16 |
2024-02-21 |
Celgene Corporation |
T cell therapy in patients who have had prior stem cell transplant
|
WO2022221126A1
(en)
|
2021-04-16 |
2022-10-20 |
Kite Pharma, Inc. |
Methods and systems for scheduling a patient-specific immunotherapy procedure
|
EP4326286A2
(en)
*
|
2021-04-23 |
2024-02-28 |
Myeloid Therapeutics, Inc. |
Compositions and methods for conditioning patients for cell therapy
|
CN117203328A
(zh)
|
2021-04-27 |
2023-12-08 |
武田药品工业株式会社 |
重组抗原呈递细胞
|
WO2022229853A1
(en)
|
2021-04-27 |
2022-11-03 |
Novartis Ag |
Viral vector production system
|
BR112023023067A2
(pt)
|
2021-05-04 |
2024-01-30 |
Regeneron Pharma |
Receptores de antigénios quiméricos com especificidade mage-a4 e usos dos mesmos
|
WO2022234009A2
(en)
|
2021-05-06 |
2022-11-10 |
Juno Therapeutics Gmbh |
Methods for stimulating and transducing t cells
|
AU2022274608A1
(en)
|
2021-05-14 |
2023-11-09 |
Kite Pharma, Inc. |
Chimeric antigen receptor t cell therapy
|
WO2022245671A1
(en)
|
2021-05-18 |
2022-11-24 |
Gilead Sciences, Inc. |
Methods of using flt3l-fc fusion proteins
|
IL308637A
(en)
|
2021-05-19 |
2024-01-01 |
Sana Biotechnology Inc |
Primary hypoimmunogenic T cells are RHD negative
|
CN117677633A
(zh)
|
2021-05-24 |
2024-03-08 |
凯德药业股份有限公司 |
基于nkg2d的嵌合抗原受体
|
CA3219478A1
(en)
*
|
2021-05-26 |
2022-12-01 |
Christina GAVEGNANO |
Jak inhibitors for managing conditions in patients with down's syndrome or other trisomy
|
KR20240013135A
(ko)
|
2021-05-27 |
2024-01-30 |
사나 바이오테크놀로지, 인크. |
조작된 hla-e 또는 hla-g를 포함하는 저면역원성 세포
|
IL308836A
(en)
|
2021-05-28 |
2024-01-01 |
Sana Biotechnology Inc |
Lipid Particles Containing Baboon Truncated Endogenous Retrovirus (BAEV) Envelope Glycoprotein and Related Methods and Uses
|
WO2022256448A2
(en)
|
2021-06-01 |
2022-12-08 |
Artisan Development Labs, Inc. |
Compositions and methods for targeting, editing, or modifying genes
|
CA3218590A1
(en)
|
2021-06-07 |
2022-12-15 |
Providence Health & Services - Oregon |
Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
|
AU2022291365A1
(en)
|
2021-06-08 |
2024-01-18 |
Kite Pharma, Inc. |
Gpc3 binding molecules
|
WO2022266538A2
(en)
|
2021-06-18 |
2022-12-22 |
Artisan Development Labs, Inc. |
Compositions and methods for targeting, editing or modifying human genes
|
EP4359511A1
(en)
|
2021-06-22 |
2024-05-01 |
Achilles Therapeutics UK Limited |
A method for producing antigen-specific t cells
|
US11926628B2
(en)
|
2021-06-23 |
2024-03-12 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
IL309378A
(en)
|
2021-06-23 |
2024-02-01 |
Gilead Sciences Inc |
DIACYLGLYERCOL KINASE MODULATING COMPOUNDS
|
WO2022271684A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
KR20240023628A
(ko)
|
2021-06-23 |
2024-02-22 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
EP4363059A1
(en)
|
2021-06-29 |
2024-05-08 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
AU2022301302A1
(en)
|
2021-07-01 |
2024-01-25 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
EP4363558A1
(en)
|
2021-07-01 |
2024-05-08 |
Kite Pharma, Inc. |
Closed-system and method for autologous and allogeneic cell therapy manufacturing
|
EP4364151A1
(en)
|
2021-07-02 |
2024-05-08 |
Kite Pharma, Inc. |
A method for identifying variants in gene products from gene constructs used in cell therapy applications
|
WO2023281097A1
(en)
|
2021-07-09 |
2023-01-12 |
Immunic Ag |
Methods for treating cancer
|
EP4370544A2
(en)
|
2021-07-14 |
2024-05-22 |
Sana Biotechnology, Inc. |
Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
|
IL310099A
(en)
*
|
2021-07-16 |
2024-03-01 |
Sana Biotechnology Inc |
Polycistronic vectors for cell-based therapies
|
WO2023004300A2
(en)
*
|
2021-07-19 |
2023-01-26 |
The Trustees Of The University Of Pennsylvania |
Chimeric antigen receptor (car)-t signaling optimization for tuning antigen activation threshold
|
US20230190799A1
(en)
*
|
2021-07-21 |
2023-06-22 |
City Of Hope |
Chimeric antigen receptor t cells targeting cea and anti-cea-il2 immunocytokines for cancer therapy
|
CA3225306A1
(en)
|
2021-07-30 |
2023-02-02 |
Kite Pharma, Inc. |
Monitoring and management of cell therapy-induced toxicities
|
WO2023014922A1
(en)
|
2021-08-04 |
2023-02-09 |
The Regents Of The University Of Colorado, A Body Corporate |
Lat activating chimeric antigen receptor t cells and methods of use thereof
|
WO2023015217A1
(en)
|
2021-08-04 |
2023-02-09 |
Sana Biotechnology, Inc. |
Use of cd4-targeted viral vectors
|
WO2023019128A1
(en)
*
|
2021-08-09 |
2023-02-16 |
The Trustees Of The University Of Pennyslvania |
Optimizing t cell differentiation state with micrornas
|
AU2022325231A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
KR20240073006A
(ko)
|
2021-08-11 |
2024-05-24 |
사나 바이오테크놀로지, 인크. |
동종이계 세포 요법을 위한 유전자 변형된 1차 세포
|
WO2023019225A2
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
AU2022326565A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
CA3227613A1
(en)
|
2021-08-11 |
2023-02-16 |
William Dowdle |
Inducible systems for altering gene expression in hypoimmunogenic cells
|
WO2023021113A1
(en)
|
2021-08-18 |
2023-02-23 |
Julius-Maximilians-Universität Würzburg |
Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs)
|
WO2023021477A1
(en)
|
2021-08-20 |
2023-02-23 |
Novartis Ag |
Methods of making chimeric antigen receptor–expressing cells
|
CA3228536A1
(en)
|
2021-08-24 |
2023-03-02 |
Yugang Guo |
Il-10 expressing cells for enhanced cancer immunotherapies
|
EP4392421A1
(en)
|
2021-08-25 |
2024-07-03 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
CN118103368A
(zh)
|
2021-08-25 |
2024-05-28 |
皮克医疗公司 |
Eif4e抑制剂及其用途
|
KR20240069799A
(ko)
|
2021-09-27 |
2024-05-20 |
소티오 바이오테크 인크. |
해당과정 경로 밖으로 포도당 대사산물을 재지향시키는 트랜스 대사 분자와 조합되는 키메라 수용체 폴리펩타이드 및 이의 치료적 용도
|
IL311981A
(en)
|
2021-10-18 |
2024-06-01 |
Kite Pharma Inc |
Signaling domains for chimeric antigen receptors
|
CN118139858A
(zh)
|
2021-10-28 |
2024-06-04 |
吉利德科学公司 |
吡地嗪-3(2h)-酮衍生物
|
AU2022376954A1
(en)
|
2021-10-29 |
2024-05-02 |
Gilead Sciences, Inc. |
Cd73 compounds
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
WO2023081735A1
(en)
|
2021-11-03 |
2023-05-11 |
Celgene Corporation |
Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
|
WO2023091909A1
(en)
|
2021-11-16 |
2023-05-25 |
Sotio Biotech Inc. |
Treatment of myxoid/round cell liposarcoma patients
|
WO2023092119A2
(en)
|
2021-11-22 |
2023-05-25 |
Ludwig Institute For Cancer Research Ltd |
Methods for predicting responsiveness to a cancer therapy
|
WO2023105000A1
(en)
|
2021-12-09 |
2023-06-15 |
Zygosity Limited |
Vector
|
TW202342498A
(zh)
|
2021-12-17 |
2023-11-01 |
美商薩那生物科技公司 |
經修飾副黏液病毒科融合醣蛋白
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
TW202342757A
(zh)
|
2021-12-17 |
2023-11-01 |
美商薩那生物科技公司 |
經修飾副黏液病毒科附著醣蛋白
|
AU2022419982A1
(en)
|
2021-12-22 |
2024-06-06 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
WO2023122615A1
(en)
|
2021-12-22 |
2023-06-29 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
CA3241438A1
(en)
|
2021-12-23 |
2023-06-29 |
Sana Biotechnology, Inc. |
Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
|
WO2023126458A1
(en)
|
2021-12-28 |
2023-07-06 |
Mnemo Therapeutics |
Immune cells with inactivated suv39h1 and modified tcr
|
WO2023129929A1
(en)
|
2021-12-30 |
2023-07-06 |
Tr1X, Inc. |
Cd4+ t cells expressing il-10 and chimeric antigen receptors and uses thereof
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023137472A2
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
|
WO2023137471A1
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
EP4215245A1
(en)
|
2022-01-19 |
2023-07-26 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Enhanced chimeric antigen receptor cells in hypoxic tumor microenvironment
|
WO2023139269A1
(en)
|
2022-01-21 |
2023-07-27 |
Mnemo Therapeutics |
Modulation of suv39h1 expression by rnas
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Parp7抑制劑
|
WO2023147515A1
(en)
|
2022-01-28 |
2023-08-03 |
Juno Therapeutics, Inc. |
Methods of manufacturing cellular compositions
|
WO2023150181A1
(en)
|
2022-02-01 |
2023-08-10 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
WO2023150518A1
(en)
|
2022-02-01 |
2023-08-10 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023154890A2
(en)
*
|
2022-02-11 |
2023-08-17 |
Fred Hutchinson Cancer Center |
Chimeric antigen receptors binding steap1
|
WO2023154578A1
(en)
|
2022-02-14 |
2023-08-17 |
Sana Biotechnology, Inc. |
Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
|
WO2023159001A1
(en)
|
2022-02-15 |
2023-08-24 |
Kite Pharma, Inc. |
Predicting adverse events from immunotherapy
|
WO2023158836A1
(en)
|
2022-02-17 |
2023-08-24 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
WO2023164440A1
(en)
|
2022-02-22 |
2023-08-31 |
Juno Therapeutics, Inc. |
Proteinase 3 (pr3) chimeric autoantibody receptor t cells and related methods and uses
|
TW202340457A
(zh)
|
2022-02-28 |
2023-10-16 |
美商凱特製藥公司 |
同種異體治療細胞
|
WO2023167882A1
(en)
|
2022-03-01 |
2023-09-07 |
Artisan Development Labs, Inc. |
Composition and methods for transgene insertion
|
WO2023172883A1
(en)
|
2022-03-07 |
2023-09-14 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
|
WO2023170606A1
(en)
|
2022-03-08 |
2023-09-14 |
Alentis Therapeutics Ag |
Use of anti-claudin-1 antibodies to increase t cell availability
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
WO2023173137A1
(en)
|
2022-03-11 |
2023-09-14 |
Yale University |
Compositions and methods for efficient and stable genetic modification of eukaryotic cells
|
TW202346277A
(zh)
|
2022-03-17 |
2023-12-01 |
美商基利科學股份有限公司 |
Ikaros鋅指家族降解劑及其用途
|
WO2023178348A1
(en)
|
2022-03-18 |
2023-09-21 |
The Regents Of The University Of Colorado, A Body Corporate |
Genetically engineered t-cell co-receptors and methods of use thereof
|
WO2023183817A1
(en)
|
2022-03-24 |
2023-09-28 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
WO2023180552A1
(en)
|
2022-03-24 |
2023-09-28 |
Institut Curie |
Immunotherapy targeting tumor transposable element derived neoantigenic peptides in glioblastoma
|
GB202204386D0
(en)
|
2022-03-28 |
2022-05-11 |
Cambridge Entpr Ltd |
Engineered immune cell platform
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
TW202345901A
(zh)
|
2022-04-05 |
2023-12-01 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
WO2023196933A1
(en)
|
2022-04-06 |
2023-10-12 |
The Regents Of The University Of Colorado, A Body Corporate |
Chimeric antigen receptor t cells and methods of use thereof
|
WO2023196921A1
(en)
|
2022-04-06 |
2023-10-12 |
The Regents Of The University Of Colorado, A Body Corporate |
Granzyme expressing t cells and methods of use
|
US20230374036A1
(en)
|
2022-04-21 |
2023-11-23 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
WO2023211972A1
(en)
|
2022-04-28 |
2023-11-02 |
Medical University Of South Carolina |
Chimeric antigen receptor modified regulatory t cells for treating cancer
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
WO2023213969A1
(en)
|
2022-05-05 |
2023-11-09 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
WO2023220644A1
(en)
|
2022-05-10 |
2023-11-16 |
Yale University |
Compositions and methods of synthetic ctla-4 tails for reprogramming of car-t cells and enhancement of anti-tumor efficacy
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
WO2023220641A2
(en)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Methods and uses related to t cell therapy and production of same
|
EP4279085A1
(en)
|
2022-05-20 |
2023-11-22 |
Mnemo Therapeutics |
Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
US11878958B2
(en)
|
2022-05-25 |
2024-01-23 |
Ikena Oncology, Inc. |
MEK inhibitors and uses thereof
|
WO2023230581A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
WO2023230276A1
(en)
|
2022-05-27 |
2023-11-30 |
Kite Pharma, Inc. |
Compositions and methods for preparing engineered lymphocytes for cell therapy
|
US20240000844A1
(en)
|
2022-05-27 |
2024-01-04 |
Kite Pharma, Inc. |
Non-viral delivery of cell therapy constructs
|
US20230399614A1
(en)
|
2022-06-09 |
2023-12-14 |
Kite Pharma, Inc. |
Methods of preparing lymphocytes for cell therapy
|
US20240010742A1
(en)
|
2022-06-10 |
2024-01-11 |
Research Development Foundation |
Engineered fcriib selective igg1 fc variants and uses thereof
|
WO2023242343A1
(en)
|
2022-06-15 |
2023-12-21 |
Immunoscape Pte. Ltd. |
Human t cell receptors specific for antigenic peptides derived from mitogen-activated protein kinase 8 interacting protein 2 (mapk8ip2), epstein-barr virus or human endogenous retrovirus, and uses thereof
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
WO2024006960A1
(en)
|
2022-06-29 |
2024-01-04 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids
|
WO2024007020A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
WO2024006929A1
(en)
|
2022-07-01 |
2024-01-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
WO2024026107A2
(en)
|
2022-07-28 |
2024-02-01 |
Lentigen Technology, Inc. |
Chimeric antigen receptor therapies for treating solid tumors
|
WO2024028364A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
WO2024030441A1
(en)
|
2022-08-02 |
2024-02-08 |
National University Corporation Hokkaido University |
Methods of improving cellular therapy with organelle complexes
|
WO2024028363A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
WO2024028365A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
WO2024033879A1
(en)
|
2022-08-10 |
2024-02-15 |
Takeda Pharmaceutical Company Limited |
Hypoimmunogenic modified cells
|
WO2024040208A1
(en)
|
2022-08-19 |
2024-02-22 |
Sotio Biotech Inc. |
Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof
|
WO2024040207A1
(en)
|
2022-08-19 |
2024-02-22 |
Sotio Biotech Inc. |
Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof
|
WO2024044779A2
(en)
|
2022-08-26 |
2024-02-29 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
|
US20240091261A1
(en)
|
2022-08-26 |
2024-03-21 |
Kite Pharma, Inc. |
Immune cell function
|
WO2024054944A1
(en)
|
2022-09-08 |
2024-03-14 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
|
WO2024056809A1
(en)
|
2022-09-15 |
2024-03-21 |
Novartis Ag |
Treatment of autoimmune disorders using chimeric antigen receptor therapy
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
WO2024064824A2
(en)
|
2022-09-21 |
2024-03-28 |
Yale University |
Compositions and methods for identification of membrane targets for enhancement of nk cell therapy
|
WO2024062138A1
(en)
|
2022-09-23 |
2024-03-28 |
Mnemo Therapeutics |
Immune cells comprising a modified suv39h1 gene
|
WO2024073583A1
(en)
|
2022-09-30 |
2024-04-04 |
Caribou Biosciences, Inc. |
Anti-ror1 chimeric antigen receptors (cars), car-nk cells and related methods
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
WO2024081820A1
(en)
|
2022-10-13 |
2024-04-18 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
WO2024089639A1
(en)
|
2022-10-26 |
2024-05-02 |
Novartis Ag |
Lentiviral formulations
|
WO2024092152A1
(en)
|
2022-10-28 |
2024-05-02 |
Kite Pharma, Inc. |
Improving efficacy and durable response of immunotherapy
|
WO2024091669A1
(en)
|
2022-10-28 |
2024-05-02 |
Ginkgo Bioworks, Inc. |
Chimeric antigen receptors comprising an intracellular domain pair
|
US20240158869A1
(en)
|
2022-10-28 |
2024-05-16 |
Kite Pharma, Inc. |
Factors for optimizing immunotherapy
|
WO2024092145A1
(en)
|
2022-10-28 |
2024-05-02 |
Kite Pharma, Inc. |
Expedited administration of engineered lymphocytes
|
WO2024097315A2
(en)
|
2022-11-02 |
2024-05-10 |
Sana Biotechnology, Inc. |
Cell therapy products and methods for producing same
|
WO2024097905A1
(en)
|
2022-11-02 |
2024-05-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
WO2024102948A1
(en)
|
2022-11-11 |
2024-05-16 |
Celgene Corporation |
Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
|
WO2024107646A1
(en)
|
2022-11-14 |
2024-05-23 |
Caribou Biosciences, Inc. |
Anti-cll-1 chimeric antigen receptors, engineered cells and related methods
|
WO2024112894A1
(en)
|
2022-11-22 |
2024-05-30 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
WO2024118593A1
(en)
|
2022-11-28 |
2024-06-06 |
Allogene Therapeutics Inc. |
Claudin 18.2 targeting chimeric antigen receptors and binding agents and uses thereof
|
WO2024119074A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Stealth lipid nanoparticle compositions for cell targeting
|
WO2024124044A1
(en)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
|
WO2024124132A1
(en)
|
2022-12-09 |
2024-06-13 |
Juno Therapeutics, Inc. |
Machine learning methods for predicting cell phenotype using holographic imaging
|
WO2024129778A2
(en)
|
2022-12-13 |
2024-06-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
|